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SUMMARY 
In the last decades two issues have significantly changed the management of pediatric patients 
affected by inherited diseases. First, the discovery that metabolic disorders can present as multiple 
malformation/mental retardation syndromes has brought innovative tools for the diagnostic work-
up, and has emphasized the pathogenic role of specific metabolic pathways derangement in 
morphogenesis defects. Second, the development of the ‘genetic medicines’ techniques has 
determined the feasibility of various innovative therapeutic approaches for a few genetic errors of 
metabolism, based on enzyme replacement, enzyme enhancement, substrate reduction, RNA 
modification and gene transfer. These two issues represent an exciting research field for 
pediatricians with a special interest in clinical genetics. 
This study is focused on the results of a four years Doctorate Research program developed at the 
Department of Pediatrics of the University of Naples “Federico II”, including two different projects. 
The first project is focused on the characterization of specific clinical, biochemical, morphological 
and molecular aspects of defects of cholesterol biosynthesis, which can be considered as typical 
examples of multiple congenital anomalies/mental retardation syndromes with metabolic bases.  
The second project is focused on the development of innovative therapeutic approaches to an 
inherited disorder of glycogen metabolism named Pompe disease, including the results of a clinical 
trial of enzyme replacement therapy and an “in vitro” study focused on an enzyme enhancement 
approach. The implications of the research results for the development of future studies are also 
discussed.  
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CHAPTER 1 
 
 
 
 
 
 
GENERAL INTRODUCTION 
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In the last decades, two issues have significantly changed the management of genetic disorders. 
Traditionally, clinical genetics has been considered to be divided in two clearly separated fields: 
dysmorphology, dealing with multiple malformation syndromes, and metabolic medicine, dealing 
with inborn errors of metabolism. In the last few years it has become clear that these two apparently 
separated fields in fact significantly overlap. To date, various multiple malformation syndromes due 
to metabolic defects have been characterized, emphasizing that metabolic derangements can play a 
major role in the pathophysiology of morphogenesis defects (Jaeken and Carchon, 2004; Martin, 
2006; Porter, 2003; Wanders and Waterham, 2005).  
The feasibility of innovative therapeutic approaches recently experimented for a few inherited 
metabolic disorders, is another issue which has had a great impact on the management of genetic 
disorders. The treatment of the more than 1,800 known monogenic hereditary disorders depends on 
the ongoing development of ‘genetic medicines’, such as therapies that use the transfer of molecular 
drugs to modify gene expression to correct or compensate for an abnormal phenotype (O’Connor et 
al., 2006). In particular, strategies include provision of the enzyme specifically lacking in the 
disease, transferring the protein itself (enzyme replacement therapy), the gene encoding the lacking 
enzyme (gene therapy), or cells producing the lacking protein (hematopoietic stem cell 
transplantation), and, finally, RNA modification in order to suppress mRNA levels, or to correct or 
add functions to the mRNA (Brady, 2006; Hodges and Cheng, 2006; O’Connor et al., 2006). Other 
therapeutic strategies include the possibility of giving drugs enhancing the activity of mutated 
proteins (enzyme enhancement therapy), or reducing the biosynthesis of substrates whose 
accumulation results to be toxic (substrate reduction therapy) (Cox, 2006; Desnick, 2004; Hodges 
and Cheng, 2006).  
The study here reported is the result of a four years Doctorate Research program developed at the 
Department of Pediatrics of the University of Naples “Federico II” from November 2002 to October 
2006. It is made of two main projects, dealing respectively with some specific aspects related to 
metabolic morphogenesis and genetic medicine. These issues represent an exciting research field 
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for pediatricians with a special interest in clinical genetics, who can play a major role in counseling 
families in which there is a child affected by an inherited condition, and in treating genetic disorders 
(Cunniff et al., 2004). The first project is focused on the characterization of specific clinical, 
biochemical, molecular and histological issues of different defects of cholesterol biosynthesis, 
which are a typical example of metabolic syndromes. The second project is aimed at developing 
innovative therapeutic approaches for an inborn error of glycogen metabolism named Pompe 
disease (glycogenosis type II). The implications of the research results for the development of 
future studies are discussed.  
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CHAPTER 2. 
 
 
 
 
 
 
PROJECT 1: MORPHOGENESIS DEFECTS  
WITH METABOLIC BASES: THE MODEL OF THE 
DEFECTS OF CHOLESTEROL BIOSYNTHESIS 
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2.1 Backgorund 
2.1.1 Dysmorphic syndromes with metabolic bases. 
A few inborn errors of metabolism can present as multiple congenital anomalies/mental retardation 
syndromes (Fernandes et al., 2000; Gorlin et al., 2001; Leonard and Morris, 2006, Scriver et al., 
2001). In these disorders, a wide pattern of malformations can be recognized, including 
craniofacial, renal, skeletal and gastrointestinal abnormalities, and central nervous system 
involvement. These defects include the defects of cholesterol biosynthesis, peroxisomal disorders, 
and congenital defects of glycosylation (Table 1; section 2.2.4). Lysosomal storage disorders are 
generally characterized by a progressive onset of dysmorphic features rather than multiple 
congenital anomalies. Amino acid disorders are generally not associated with multiple 
malformations, with the exception of the defect of glutamine synthase, presenting severe brain 
malformations, limb defects, and dysmorphic facies. Dysmorphic features associated with central 
nervous system involvement can be noted in various other metabolic conditions (Table 1, section 
2.2.4), including amino acid disorders, such as homocystinuria, respiratory chain disorders, and 
molybdenum cofactor deficiency. Nevertheless, these disorders are generally not associated with 
the presence of major malformations of internal organs. Finally, a few skeletal dysplasias, also 
presenting with dysmorphic features, are caused by metabolic defects, such as the chondrodysplasia 
punctata group, defects of bone mineralization and some lysosomal storage disorders (Hall, 2001). 
The definition of the clinical and biochemical phenotypes of the metabolic syndromes, and the 
characterization of their molecular bases, is crucial to increase the rate of diagnoses and to correlate 
specific patterns of anomalies to the underlying pathogenic mechanisms. 
 
2.1.2 Defects of cholesterol biosynthesis (DCB). 
Defects of cholesterol biosynthesis (DCB) are a heterogeneous group of metabolic disorders 
associated in the majority of cases with multiple malformations and mental retardation.  
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Smith-Lemli-Opitz syndrome (SLOS) is the most frequent and better characterized DBC (Yu and 
Patel, 2005). This condition is characterized by developmental delay, typical facial dysmorphisms, 
limb anomalies, incomplete development of male genitalia and possible association with 
malformations of internal organs.  The clinical phenotype is extremely variable, ranging from 
miscarried fetuses with multiple malformations including holoprosencephaly, to patients presenting 
with mild developmental delay and no major malformations. 
SLOS is due to the deficiency of the 7-dehydrocholesterol reductase (DHCR7), the enzyme that 
catalyzes the last step of cholesterol biosynthesis. SLOS patients typically have low levels of 
cholesterol and high levels of its precursor 7-dehydrocholesterol (7-DHC) in the blood and other 
tissues. The gene of the SLOS has been cloned (DHCR7) and to date more than 120 mutations have 
been reported in the literature (Yu and Patel, 2005). The inheritance of the syndrome is autosomal 
recessive and the overall incidence is estimated to be around 1:40000 live births. To date there is no 
effective therapy for this condition. Patients can follow a high cholesterol diet (100-300mg/Kg/day 
of pure cholesterol added to a normal diet). The rationale of this approach is to provide the lacking 
metabolite, and to inhibit at the same time the endogenous biosynthesis of cholesterol and, 
therefore, the production of 7-DHC. Nevertheless, unfortunately, this therapeutic approach does not 
seem to have a significant effect on the neurological outcome (Yu and Patel, 2005). The other DCB 
known to date are reported in Table 2 (section 2.2.4). 
 
2.1.3 Diagnosis of SLOS and other DCB at the University of Naples Federico II 
Since 1994 the biochemical diagnosis of the SLOS has been performed at the Department of 
Pediatrics by UV Spectrophotometry (UVS) qualitative analysis of the 7-DHC (Guzzetta et al., 
1996). The samples which resulted to be positive to the qualitative analysis by UVS, and negative 
samples collected from patients with clinical features possibly suggesting DCB other than SLOS, 
were analyzed also by quantitative Gas Chromatography/Mass Spectrometry  (GC/MS) at the 
Department of Biochemistry and Medical Biotechnology of our University (Corso et al., 2002; 
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Guzzetta et al., 1996). Until November 2002, 132 biological samples had been analyzed, and 19 
SLOS cases had been diagnosed. In 9 patients, molecular analysis of the DHCR7 gene was carried 
out at the Department of Pediatrics, Federico II University (De Brasi et al., 1998).  
Furthermore, in collaboration with Department of Biochemistry and Medical Biotechnology of this 
University, and the Department of Pediatrics of the University of Modena and Reggio Emilia, Italy, 
we described in 2002 the first patient affected by lathosterolosis (Brunetti-Pierri et al., 2002). This 
rare DCB, due to the deficiency of 3-beta-hydroxysteroid-delta-5-desaturase (SC5D), is 
characterized by multiple malformations, mental retardation and liver involvement, associated with 
high levels of the cholesterol precursor lathosterol in the biological fluids and tissues (Brunetti-
Pierri et al., 2002).  
Since the year 2000, our Hospital has been recognized as a national referral centre for the diagnosis 
of DCB. 
 
2.2 EXPERIMENTAL WORK. 
2.2.1 Outline of the Project 
The overall aim of this project was the creation of a database of Italian patients affected by DCB in 
order to characterize specific clinical, biochemical, molecular and morphological aspects, and 
possible pathogenic mechanisms of DCB, and to promote international collaborative studies in this 
field. 
 
2.2.2 Patients and Methods 
In the years 2002-2006, we collected 176 biological samples (blood, skin fibroblasts, pathological 
samples) from patients presenting with clinical pictures compatible with DCB, as evaluated by 
geneticists and pediatricians in Italy. Plasma and serum samples were collected and kept frozen at -
20°C protected from light until analysis. These samples were analyzed by UVS at the Department 
of Pediatrics Federico II University and/or GC/MS at the Department of Biochemistry and Medical 
 17 
Biotechnology Federico II University. In three cases, skin fibroblasts were collected, cultivated in 
delipidated medium for 7 days and analyzed by GC/MS for sterol profiling, as previously reported  
(Brunetti-Pierri et al., 2002; Corso et al., 2002; Guzzetta et al., 1996). For one historical case 
(multiple malformed fetus previously aborted), only pathological samples were available and sterol 
analysis was therefore not possible. DNA was extracted from the pathological samples available, 
and analyzed by molecular analysis of the SC5DL gene (Brunetti-Pierri et al., 2002) at the 
Department of Pediatrics, Federico II University. 
A Database for Italian DCB patients diagnosed at the Federico II University of Naples was set up. 
The information collected included the main clinical features, sterol profile at diagnosis, and 
molecular background when known. A clinical severity score was assessed according to previously 
proposed standards (Kelley and Hennekam, 2000; Witsch-Baumgartner et al., 2000) for all SLOS 
patients with clinical features available.  
 
2.2.3 Results 
During the research period, we diagnosed: 
• A further patient with lathosterolosis by molecular analysis of the SC5DL gene, in a multiple 
malformed fetus, sibling of the first case described. This patient is extensively described in 
section 2.2.5.  
• A patient with chondrodysplasia punctata X-linked dominant (CDPX2, Conradi-
Hunermann-Happle), by sterol profiling of skin fibroblasts. To the best of our knowledge, 
this is the first patient biochemically diagnosed in Italy.  
• Six further SLOS patients. 
 
Data from the newly diagnosed cases were pooled together with those of the patients previously 
diagnosed at the Federico II University of Naples in the Database. The main clinical, biochemical, 
molecular features of the diagnosed patients with DCB are summarized in Table 3 (section 2.2.4). 
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A few studies were then performed on these patients, focusing on the following specific topics:  
• Characterization of the phenotype of lathosterolosis, extensively reported in the “Specific 
aim 1”, and appendix 2.5.1 of this chapter. 
• Characterization of liver involvement in DCB, extensively reported in the “Specific aim 2” 
and appendix 2.5.2. 
• Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome, extensively reported 
in the “Specific aim 3” and appendix 2.5.3. 
These studies particularly focused on possible pathogenic mechanisms responsible for clinical and 
biochemical abnormalities found in the DCB patients recruited. 
 
Given the availability of the information collected in the Database of the Italian DCB patients, and 
of the biological material collected for biochemical and molecular diagnosis, we could join an 
international scientific collaborative study coordinated by Dr. M. Witsch-Baumgartner, Department 
of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck, Austria. This study was 
aimed at characterizing the genetic background of SLOS patients by molecular analysis of the 
DHCR7 gene according to previous reports (Witsch-Baumgartner et al., 2000), in order to 
investigate possible pathogenic mechanisms of the disease. More in details, these studies focused on 
the following specific topics: 
• Multicentric collaborative study on factors modifying the phenotypic severity in the Smith-
Lemli-Opitz syndrome, extensively reported in the “Specific aim 4” and appendix 2.5.4. 
• Characterization of the DHCR7 mutational spectra in Spain and Italy, extensively reported 
in the “Specific aim 4” and appendix 2.5.5. 
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2.2.4 Tables 1-3. 
 
 
 
Table 1 
Examples of inborn errors of metabolism presenting with congenital anomalies and/or dysmorphic 
features. 
 
PRESENTING PHENOTYPES DISEASES 
Multiple congenital anomalies/mental 
retardation syndromes 
Defects of cholesterol biosynthesis 
Peroxisomal disorders 
Congenital disorders of glycosylation 
Glutaric aciduria type II (multiple acyl-Coa dehydrogenase 
deficiency) 
Carnitine palmitoyl-transferase-II deficiency 
Other very rare disorders (defect of glutamine synthase; beta-
hydroxyisobutyryl-CoA deacylase deficiency) 
Dysmorphic features and/or central 
nervous system abnormalities, 
generally without major congenital 
anomalies of internal organs 
Pyruvate decarboxylase deficiency  
Respiratory chain disorders, congenital lactic acidosis 
Other organic acidurias (i.e., 3-hydroxyisobutyric aciduria) 
Homocystinuria  
Glycine encephalopathy 
Molybdenum cofactor deficiency  
Lysosomal storage disorders * 
Predominant skeletal dysplasia Chondrodysplasias Punctata (X-linked recessive; Peroxisomal 
disorders; Defects of cholesterol biosynthesis)  
Sulfate transport disorders (Diastrophic dysplasia group) 
Dyplasia with defective mineralization (Hypophosphatasia; 
Hypophosphatemic rickets) 
Inborn errors of collagen  
Lysosomal storage disorders * 
 
* Generally characterized by a progressive development of dysmorphic features without major 
congenital abnormalities  
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Table 2. 
Defects of cholesterol biosynthesis known to date. 
 
 
DBC 
OMIM Enzymatic defect Gene Inheritance Main phenotypic features 
Mevalonic aciduria #610377  Mevalonate Kinase MVK Autosomal 
recessive 
Developmental delay, cerebellar ataxia, cataracts, dysmorphic facies, 
anemia, hepatosplenomegaly, diarrhea and malabsorption 
Hyper IgD syndrome #260920 Mevalonate Kinase MVK Autosomal 
recessive 
Recurrent febrile crises, lymphadenopathy, splenomegaly, abdominal pain, 
diarrhea, vomiting, arthritis, rash, elevated polyclonal IgD 
Smith-Lemli-Opitz syndrome #270400 3-beta-hydroxysterol-
delta-7-reductase 
DHCR7 Autosomal 
recessive 
Microcephaly, typical facies, mental retardation, limb defects including 2-3 
toe syndactyly and possible polydactyly, incomplete development of male 
genitalia, midline defects, malformations possibly involving every organs 
and systems 
Desmosterolosis #602398 3-beta-hydroxysterol-
delta-24-reductase 
DHCR24  Autosomal 
recessive 
Microcephaly or macrocephaly, facial dysmorphisms, gingival nodules, 
mental retardation, abnormal development of  male and female genitalia, 
heart defects, possible osteosclerosis and rhizomelic shortening 
Lathosterolosis #607330 3-beta-hydroxysteroid 
-delta-5-desaturase 
SC5DL Autosomal 
recessive 
Microcephaly, typical facies, mental retardation, skeletal defects including 
toe syndactyly and polydactyly, renal anomalies, incomplete development of 
male genitalia, liver involvement 
CHILD (Congenital 
Hemidysplasia with 
Ichthyosiform erythroderma 
and Limb Defects) syndrome 
#308050 NAD(P)H steroid 
dehydrogenase-like 
protein 
NSDHL X-linked 
dominant 
Hemilateral limb defects and ichthyosiform erythroderma, with ipsilateral 
brain hypoplasia and possible malformations of internal organs, scoliosis, 
heart defects, epiphyseal stippling 
CDPX2/Chondrodysplasia 
punctata X-linked dominant/ 
Conradi-Hunermann-Happle 
Syndrome 
#302960 3-beta-hydroxyste-
roid-delta(8),delta(7)-
isomerase/emopamil-
binding protein 
EBP X-linked 
dominant 
Cataract, epiphyseal stippling, tracheal calcifications, scoliosis, 
hemivertebrae, congenital ichthyosiform erythroderma, follicular 
atrophoderma, coarse, sparse hair, patchy areas of alopecia, Dandy-Walker 
malformation, ventriculomegaly 
Pelger-Huet anomaly #169400 Lamin B receptor LBR Autosomal 
dominant 
Heterozygote: hypolobulated (bilobed or rod-like) granulocyte nuclei 
Homozygote: ovoid granulocyte nuclei, macrocephaly, dysmorphisms, 
ventricular septal defect, polydactyly, short metacarpals, developmental 
delay, seizures. 
Greenberg dysplasia/ 
Hydrops-Ectopic 
Calcification-Moth-Eaten 
Skeletal Dysplasia 
#215140 Lamin B receptor LBR Autosomal 
recessive 
Heterozygote: hypolobulated (bilobed or rod-like) granulocyte nuclei 
Homozygous: large head, punctate calcifications, laryngeal and tracheal 
calcifications, platyspondyly with multiple extra ossification centers, 
rhizomelia, moth-eaten (fragmented) long bones, polydactyly, 
extramedullary erythropoiesis, severe hydrops 
Related disorder: Antley-
Bixler Syndrome-Like 
Phenotype with disordered 
steroidogenesis 
#201750 Cytochrome P450 
oxidoreductase 
POR Autosomal 
recessive 
Craniosynostosis, choanal atresia or stenosis, proptosis, narrow chest, 
ambiguous genitalia (males and females) , femoral bowing, fractures, 
camptodactyly 
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Table 3. 
Database of the clinical, biochemical and molecular features of patients affected by defects of cholesterol 
biosynthesis with clinical information available, diagnosed at the Federico II University of Naples. 
 
 DIAGNOSIS 
 SLOS  LS CDPX2 
FEATURES (% of  cases showing the 
feature) 
(number of 
cases) 
 
Gender 15M/10F 2F 1F 
Mental retardation + (100) + (1/1) - 
Postnatal growth retardation + (96) + (1/1) + 
Microcrephaly + (88) + (2/2) - 
Structural brain anomalies + (52) + (1/2) - 
Facial dysmorphisms + (100) + (2/2) + 
Cataract + (12) + (1/2) + 
Cleft palate* + (56) - - 
Congenital heart defect + (28) - - 
Renal anomalies + (8) + (1/2) - 
Male genital anomalies + (100) NA NA 
2/3 toe syndactyly + (92) + (1/2) - 
Polydactyly + (28) + (2/2) - 
Vertebral midline defects  -  + (2/2) - 
Pyloric stenosis + (36) - - 
Colonic aganglionosis + (12) - - 
Severity score (mean + SD) 5.4 + 2.8 NA NA 
7-DHC qualitative analysis by 
UV Spettrophotometry 
Positive (100%) Negative (1/1) NA** 
Sterol profile at diagnosis 
analyzed by GC/MS (mean + 
SD) 
Ch: 25,3 +14.9 mg/dl 
7DHC: 25 + 22.8 mg/dl 
Ch: 89.9 mg/dl 
Lth: 6.69 mg/dl   
Ch: 60.5 
µg/mg/pr 
Zym: 13.3 
µg/mg/pr** 
DHCR7 alleles identified in 
15/25 SLOS patients (Number 
of alleles identified) 
p.T93M (8) 
IVS8-1G>C (6) 
p.E448K (4) 
p.H119L (2) 
p.R352W (2) 
p.I58F (1) 
p.W151X (1) 
p.E288K (1)  
p.R404C (1) 
p.N407Y (1) 
p.F239L/N240S (cis) (1)  
(385-412 and IVS5+1-5)del (1) 
NA NA 
SC5DL alleles identified in LS 
patients (siblings) (Number) 
NA R29Q (2)  
G211D (2) 
NA 
 
SLOS: Smith-Lemli-Opitz syndrome; LS: Lathosterolosis; CDPX2: Chondrodysplasia Punctata X-Linked 
Dominant; GC/MS: Gas Chromatography/Mass Spectrometry; UVS: UV Spettrophotometry; Ch: 
cholesterol; 7DHC: 7-dehydrocholesterol; Lth: lathosterol; Zym: zymosterol; NA: not applicable; * 
including cleft soft palate, submucous cleft and cleft uvula; ** the patient affected by CDPX2 was 
diagnosed by sterol analysis of skin fibroblasts after 7 days of culture in delipidated medium by GC/MS.  
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2.2.5 Specific Aim 1. 
CHARACTERIZATION OF THE PHENOTYPE OF LATHOSTEROLOSIS. 
Lathosterolosis is a rare DCB due to the deficiency of 3-β-hydroxysteroid-∆5-desaturase. Only two 
patients have been described to date, both presenting with multiple malformations, mental 
retardation, and liver involvement. In addition in one of them pathological examination revealed 
mucolipidosis-like inclusions on optic microscopy analysis, and peculiar lysosomal lamellar bodies 
on electron microscopy analysis. This study is focused on a better characterization of the clinical 
phenotype of LS.   
We describe a further case in a fetus, sibling of the first patient reported, presenting with neural tube 
defect, craniofacial and limb anomalies, and prenatal liver involvement. The fetal phenotype 
suggests the possible occurrence of significant intrafamilial variability in LS, expands the 
phenotypic spectrum of the disease, and suggests an important role of cholesterol biosynthesis 
derangement in neural tube closure.  
Histological examination of autoptic samples from the fetus and skin fibroblasts from the living 
sibling suggested that the mucolipidosis-like picture previously reported is not a constant feature of 
LS, being possibly associated with the most severe phenotypes, but confirmed the ultrastructural 
finding of lamellar inclusions.  
The LS phenotype appears to be characterized by the peculiar association of a recognizable pattern 
of multiple malformations, involving particularly axial and appendicular skeleton, central nervous 
and urogenital systems, and lyososmal storage. This condition shows a significant overlapping with 
other DCB such as the Smith-Lemli-Opitz syndrome, and shares also similarities with defects of 
cholesterol trafficking (Niemann-Pick type C disease), and defects of plant sterols metabolism 
(Sitosterolemia), suggesting intriguing pathogenic links among these conditions.  
This study if fully reported in appendix 2.5.1. 
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2.2.6 Specific Aim 2.  
CHARACTERIZATION OF LIVER INVOLVEMENT IN DEFECTS OF CHOLESTEROL 
BIOSYNTHESIS  
Inborn defects of cholesterol biosynthesis are a group of metabolic disorders presenting with mental 
retardation and multiple congenital anomalies (MCA/MR syndromes). Functional and structural 
liver involvement has been reported as a rare (2.5-6%) complication of the Smith-Lemli-Opitz 
syndrome (SLOS) and it has not been fully characterized.  
In this study we report on a long-term follow-up study of 4 patients with SLOS, and 1 case with 
lathosterolosis who presented with liver disease and underwent an extensive diagnostic work-up. 
Reports of liver involvement in cholesterol biosynthesis defects are reviewed.  
Two main different patterns of liver involvement emerged: progressive cholestasis, and stable 
isolated hypertransaminasemia. In our series, the first pattern was found in 2 patients with SLOS 
and 1 with lathosterolosis, and the second in 2 SLOS cases. Cholestasis was associated with early 
lethality and normal serum γ-glutamyl-transferase (GGT) levels in SLOS, while possible prolonged 
survival and high GGT levels were seen in lathosterolosis. Hepatic fibrosis was present in both 
conditions. Liver biopsy performed in one of our SLOS patients with isolated 
hypertransaminasemia, showed only mild hydropic degeneration of the hepatocytes. The presence 
of liver involvement in 16% of the SLOS patients diagnosed at our Center suggests that this 
complication might have been underestimated in previously reported cases, possibly overshadowed 
by the severity of multiple malformations. Fetal hepatopathy, cholestasis, and isolated 
hypertransaminasemia can occur also in other disorders of cholesterol biosynthesis, such as 
mevalonic aciduria, desmosterolosis, Conradi-Hünermann syndrome, Greenberg dysplasia  and 
Pelger-Huët homozygosity syndrome. This group of inherited disorders should be considered in the 
differential diagnosis of patients presenting with liver disease associated with developmental delay 
and/or multiple malformations. Periodic liver function evaluations are recommended in these 
patients. This study is fully reported in Appendix 2.5.2. 
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2.2.7 Specific Aim 3.  
VITAMIN D STATUS IN PATIENTS AFFECTED BY SMITH-LEMLI-OPITZ 
SYNDROME. 
Smith-Lemli-Opitz syndrome (SLOS) is an inborn error of cholesterol biosynthesis characterized by 
developmental delay and multiple malformations. Some of the patients have skin photosensitivity 
and therefore tend to avoid direct exposure to sunlight. SLOS patients typically have low levels of 
cholesterol and abnormally high levels of its precursor 7-dehydrocholesterol (7-DHC) in biological 
fluids and tissues. 7-DHC is also a precursor in the cutaneous synthesis of vitamin D. Sunlight 
exposure plays a major role in this pathway and reactions transforming 7-DHC into vitamin D and 
then into 25-hydroxy-vitamin D are known to be not specifically regulated. The aim of this study is 
to evaluate vitamin D status in SLOS patients. 
We measured 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D serum levels and markers of 
calcium metabolism in 5 SLOS patients.  
Despite abnormally high levels of 7-DHC circulating levels of vitamin D metabolites were not 
significantly different from appropriate controls matched for sex, age and season of blood 
collection. The analysis of historical serum samples stored in our laboratory from the same cases 
plus 10 other SLOS patients further supported these findings.  
Our data suggest that SLOS patients have a peculiar vitamin D metabolism preventing them from 
vitamin D intoxication. This appears to be due in most cases to decreased transformation of 7-DHC 
into 25-hydroxy-vitamin D, perhaps depending on reduced sunlight exposure as a consequence of 
photosensitivity. Speculations on possible alternative mechanisms are discussed.  
This study is fully reported in Appendix 2.5.3. 
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2.2.8 Specific aim 4 
DATABASE OF ITALIAN PATIENTS WITH DCB AND INTERNATIONAL 
COLLABORATIVE STUDIES. 
The clinical information collected in the Database, and the availability of biological material 
collected for biochemical or molecular diagnoses, made it possible to join the international 
collaborative studies coordinated by the Department of Medical Genetics, Molecular and Clinical 
Pharmacology Innsbruck, Austria on the characterization of specific molecular aspects of the 
Smith-Lemli-Opitz syndrome. DNA was collected from six further SLOS patients and their parents 
when available. In one case, DHCR7 molecular analysis was performed in our laboratory according 
to previous report (De Brasi et al., 1998). In five SLOS cases, DHCR7 molecular analysis was 
performed in Austria. DNA was collected from parents of SLOS patients and sent to Austria for 
molecular study on SLOS heterozygouses. The following collaborative studies were performed. 
 
Maternal apo E genotype is a modifier of the Smith-Lemli-Opitz syndrome 
In the Smith-Lemli-Opitz syndrome, the growing affected embryos are dependent on exogenous 
(maternal) sources of cholesterol. This study is focused on evaluating whether apolipoprotein E, a 
major component of the cholesterol transport system in human beings, is a modifier of the clinical 
severity of Smith-Lemli-Opitz syndrome. 
Common apo E, DHCR7, and LDLR genotypes were determined in 137 biochemically 
characterized European SLOS patients and 59 of their parents. 
A significant correlation was found between patients’ clinical severity scores and maternal apo E 
genotypes (p = 0.028) but not between severity scores and patients’ or paternal apo E genotypes. In 
line with their effects on serum cholesterol levels, the maternal apo e2 genotypes were associated 
with a severe Smith-Lemli-Opitz syndrome phenotype, whereas apo E genotypes without the e2 
allele were associated with a milder phenotype. The correlation of maternal apo E genotype with 
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disease severity persisted after stratification for DHCR7 genotype. There was no association of 
Smith-Lemli-Opitz syndrome severity with LDLR gene variation. 
These results suggest that the efficiency of cholesterol transport from the mother to the embryo is 
affected by the maternal apo E genotype and extend the role of apo E and its disease associations to 
modulation of embryonic development and malformations. This study is extensively reported in 
Appendix 2.5.4.  
 
Delineation of the DHCR7 Mutational Spectra in Spain and Italy 
 The DHCR7 mutational spectra differ significantly in different areas of Europe, and several 
common putative founder mutations account for a substantial fraction of all mutations in some 
ethnic groups. This study was focused on the molecular analysis of 47 SLOS patients of Ashkenazi 
Jewish, Austrian, British, German, Italian, Irish, Polish, Portuguese, and Spanish origins. Fourteen 
newly identified mutations were found in 18 SLOS patients. Half of the new mutations were in the 
transmembrane domains of the protein. In addition, there were two null mutations, one mutation in 
the 4th cytoplasmic loop, two mutations in the first and last codons, and three mutations in other 
regions such as the second cytoplasmic loop and the first endoplasmic loop. The analysis included 
20 Spanish and 12 Italian SLOS patients and revealed very different mutation spectra in these 
patients compared to previously described patients from Czechoslovakia, Germany, Poland, and the 
UK and implicated p.Thr93Met on the J haplotype as the most frequent Mediterranean founder 
mutation. This study is extensively reported in Appendix 2.5.5. 
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2.3 Conclusions  
The setting up of a database of Italian patients affected by DCB allowed us to perform a few 
research studies aimed at characterizing specific clinical, biochemical, morphological and molecular 
aspects of  SLOS and lathosterolosis, focusing particularly on the possible pathogenic mechanisms 
of these diseases.  
Given their clinical variability, the definition of the phenotypic spectrum of DCB is crucial to 
increase the rate of diagnosis: our data suggest that patients presenting with a variable association of 
multiple malformations including neural tube defects, developmental delay, and liver disease should 
undergo plasma or tissue sterol analysis. The DCB clinical variability has been partially explained 
by one of the molecular collaborative studies performed, which demonstrated that maternal ApoE 
genotype can play a crucial role in modifying the SLOS phenotypic severity. Further studies are 
necessary to evaluate the possible presence of phenotypic modifier also for other DCB. The other 
collaborative molecular study confirmed our previous observation that the T93M mutation is 
particularly frequent in SLOS patients coming from the Mediterranean area (De Brasi et al., 1998). 
The pattern of malformations observed in DCB might suggest a correlation with specific underlying 
pathogenic mechanisms. First, the axial and appendicular skeletal malformations observed in 
lathosterolosis might be partially explained by a functional disruption in the hedgehog signaling 
pathway, secondary to the primary defect in cholesterol biosynthesis. Furthermore, our data 
suggested that various different factors might contribute to the pathogenesis of the liver 
involvement observed in DCB, including insufficient cholesterol availability, a possible secondary 
disruption in bile acid metabolism in SLOS, and a secondary disruption in plant sterol metabolism 
in lathosterolosis. Finally, the lysosomal lamellar inclusions demonstrated in lathosterolosis and 
SLOS, supported the existence a secondary disruption of the intracellular cholesterol trafficking at 
least in these two diseases and, possibly, in other DBC.  
Our data suggested that SLOS patients have a peculiar vitamin D metabolism, protecting them from 
vitamin D intoxication. It has been hypothesized that the relatively high incidence of SLOS in some 
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European ethnic groups, the relatively low percentage of patients reported to be born to 
consanguineous parents, and the more severe enzymatic defects caused by the most common 
mutations compared with the less common ones, are suggestive of a heterozygote advantage. An 
increased vitamin D biosynthesis rate has been proposed as a possible heterozygote advantage 
(Kelly and Hennekam, 2000): therefore, further studies are required to evaluate vitamin D 
metabolism in SLOS carriers.  
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ABSTRACT 
Lathosterolosis (LS) is a defect of cholesterol biosynthesis (DCB) due to the deficiency of 3-β-
hydroxysteroid-∆5-desaturase. Only two patients have been described to date, both presenting with 
multiple malformations, mental retardation, and liver involvement. In addition in one of them 
pathological examination revealed mucolipidosis-like inclusions on optic microscopy analysis, and 
peculiar lysosomal lamellar bodies on electron microscopy analysis. This study is focused on a 
better characterization of the clinical phenotype of LS.   
We describe a further case in a fetus, sibling of the first patient reported, presenting with neural tube 
defect, craniofacial and limb anomalies, and prenatal liver involvement. The fetal phenotype 
suggests the possible occurrence of significant intrafamilial variability in LS, expands the 
phenotypic spectrum of the disease, and suggests an important role of cholesterol biosynthesis 
derangement in neural tube closure.  
Histological examination of autoptic samples from the fetus and skin fibroblasts from the living 
sibling suggested that the mucolipidosis-like picture previously reported is not a constant feature of 
LS, being possibly associated with the most severe phenotypes, but confirmed the ultrastructural 
finding of lamellar inclusions.  
The LS phenotype appears to be characterized by the peculiar association of a recognizable pattern 
of multiple malformations, involving particularly axial and appendicular skeleton, central nervous 
and urogenital systems, and lyososmal storage. This condition shows a significant overlapping with 
other DCB such as the Smith-Lemli-Opitz syndrome, and shares also similarities with defects of 
cholesterol trafficking (Niemann-Pick type C disease), and defects of plant sterols metabolism 
(Sitosterolemia), suggesting intriguing pathogenic links among these conditions.  
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INTRODUCTION 
Defects of cholesterol biosynthesis (DCB) are a group of inherited metabolic diseases 
associated with multiple congenital anomalies and mental retardation (MCA/MR). Smith-Lemli-
Opitz syndrome (SLOS, OMIM: #270400), due to the deficiency of the enzyme 7-
dehydrocholesterol reductase (DHCR7), is the most frequent and better characterized example of 
DCB [Kelley and Hennekam, 2000; Porter et al., 2003]. SLOS patients present with typical facial 
dysmorphisms, limb anomalies, incomplete development of male genitalia, and malformations 
possibly involving all organs and systems. Lathosterolosis (LS, OMIM: #607330) is an additional 
example of this group of metabolic syndromes [Brunetti-Pierri et al., 2002; Krakowiak et al., 2003; 
Parnes et al., 1990; Rossi et al., 2005]. This disorder is due to the deficiency of 3-β-hydroxysteroid-
∆
5
-desaturase (SC5D), the enzyme immediately upstream DHCR7, which catalyzes the 
transformation of lathosterol into 7-dehydrocholesterol. Inheritance is autosomal recessive. LS is 
very rare: in fact after the characterization of the first case [Brunetti-Pierri et al., 2002], only 
another LS patient has been diagnosed post-mortem [Krakowiak et al., 2003]. Interestingly the latter 
case showed massive mucolipidosis-like inclusions [Krakowiak et al., 2003; Parnes et al., 1990], a 
feature not evident on histological examination of a liver biopsy performed in the first case reported 
[Rossi et al., 2005]. In this study, we describe a new LS case further expanding the clinical 
spectrum of the disease, and we report updated clinical and morphological information about the 
first patient diagnosed [Brunetti-Pierri et al., 2002; Rossi et al, 2005]. We also compare the 
phenotypic features observed in LS with those reported in the SLOS, and other defects of sterol 
metabolism. The aim of this study is a better characterization of the clinical phenotype of LS.  
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CLINICAL REPORTS 
PATIENT 1 
Clinical features. The first sibling of the living girl with LS [Brunetti-Pierri et al., 2002, Rossi et 
al, 2005], was a historical fetal case, aborted at 21 weeks gestation, after a routine ultrasound scan 
revealed multiple malformations. Neither maternal diabetes, nor teratogenic exposure was reported. 
Around conceiving the mother was on adequate folate supplementation. Clinical features were 
reviewed after a diagnosis of LS was made in the living sister. On macroscopic examination, weight 
and length appeared to be appropriate for gestational age (290 g and 21 cm respectively). Post-
mortem findings included multiple congenital anomalies such as Type II Arnold Chiari 
malformation, microcephaly, postaxial hexadactyly of upper and lower limbs, bilateral clubfeet and 
lumbosacral meningocele (1.5 x 1 cm).  No malformations were reported in other organs. 
Unfortunately neither photos nor radiographs were available. Chromosome analysis showed a 
normal female karyotype. A diagnosis of LS was suspected on the bases of the pattern of limb and 
craniofacial anomalies. Molecular analysis of the SC5DL gene, performed as previously described 
[Brunetti-Pierri et al., 2002] in DNA samples obtained from stored pathological specimens, 
revealed the same two mutations found in the living sister (R29Q/86G→A in exon 1, and 
G211D/632G→A in exon 4), thus confirming the diagnosis.  
 
Histological features. Histological examination of fetal samples from thymus, spleen, pancreas, 
liver, kidneys, adrenals, uterus, ovaries, heart, lungs, spinal cord and brain was carried out by optic 
microscopy using the following stains: hematoxylin-eosin; special histochemical stains like PAS 
and PAS after diastase digestion, Hale’s dialyzed colloidal iron for acid MPS; immunostaining for 
HepPar1 in liver histology. In none of the histological specimens examined, cells with storage or 
foamy material were noted. In particular, liver tissue showed normal portal tracts, and marked 
extramedullary hematopoiesis leading to atrophy of hepatocytic laminae (Fig.1). Hemosiderinic 
pigment within periportal hepatocytes and Kupffer cells were also present (Fig.1 detail). Hypoxic 
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changes were noted in cerebral cortex and white matter, likely due to abortion procedures. No 
significant histological changes were noted in the other organs. 
 
PATIENT 2 
Clinical features. This girl with LS, presented with developmental delay, craniofacial anomalies, 
post-axial polydactyly of the left foot, syndactyly of toes, horseshoe kidneys, bilobate gallbladder 
and progressive intra-hepatic cholestasis [Brunetti-Pierri et al., 2002; Rossi et al., 2005]. She was 
reviewed at the age of 7 years. During follow-up, her gestaltic facial appearance had significantly 
changed. In the neonatal period the girl showed a striking microcephaly, with receding forehead, 
eyelid ptosis, prominent nose with bulbous nasal tip and micrognathia with protruding upper lip 
(Fig.2A). In the following years, physical examination revealed microcephaly with bitemporal 
narrowing, epicanthic folds, eyelid ptosis, a small nose with anteverted nares, a small chin, puffy 
cheeks, and a long philtrum (Fig.2B-C). At 6 years of age, small bilateral lens opacities became 
evident on ophthalmological examinations, which subsequently evolved in total cataracts of the 
right eye, requiring surgery. The cholestasis severity was progressive with persistently elevated 
serum levels of transaminases, bilirubin and ammonia as previously described [Rossi et al., 2005], 
and portal hypertension was noted on abdominal Doppler ultrasound at 7 years of age. In spite of 
multi-vitamin supplementation, low levels of vitamin A and E were repeatedly detected, as well as 
abnormal clotting tests. The girl experienced two pathological fractures and DEXA scan performed 
at 7.5 years of age, revealed severe generalized osteoporosis (Z-score: - 4.9). She also developed a 
peculiar feeding behavior showing frequent vomiting and a striking fishy body odor after tasting 
particular foods, such as fish, cow meet, milk and derivatives, which she tended to avoid 
spontaneously: urine trimethylamine analysis by Protonic Nuclear Magnetic Resonance resulted to 
be negative [Maschke et al., 1997], and no clear explanation was found for this phenomenon.  
Blood films revealed the presence of abnormally shaped red cells with anisopoikilocytosis 
(MCV: 89.3fl; normal values: 82-98; RDW: 18.4%; normal values 11-14), acanthocytes, 
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schistocytes,  and large platelet (mean platelet volume: 12.4 fl; normal range: 9.1-12.3); vacuolated 
monocytes were also noted (Fig. 3). Full blood count repeatedly showed normal hemoglobin levels 
(range: 12.2-13.2 g/dl) and low to normal platelet count (range: 121-219 x 103/µl; normal range: 
150-400 x 103/µl).  
At 7 years of age, plasma sterol profile by Gas-Chromatography-Mass Spectrometry showed 
normal levels of cholesterol (155 mg/dl), persistently high levels of lathosterol (17 mg/dl), and 
abnormally high levels of other methylated sterols, such as in the previously performed 
determinations [Brunetti-Pierri et al., 2002]: these metabolites were subsequently identified as the 
plant sterols sitosterol (0.7mg/dl), campesterol (0.5mg/dl) and stigmasterol (0.2mg/dl) (total plant 
sterols: 0.8% of total sterols detected; control range: 0.36 + 0.08) (Pianese and Corso, personal 
communication).  
 
Radiological features. A skeletal survey, performed at 11 months of age, showed sagittal clefting 
of the eight thoracic vertebra (“butterfly” shaped) (Fig. 4A), as previously mentioned [Brunetti-
Pierri et al., 2002]. In addition, the left foot showed postaxial polydactyly characterized by 
ossification of a proximal phalanx, and an abnormal widening of the fifth metatarsal representing an 
attempt at duplication. Radiologically, postaxial polydactyly was evident also in the right foot, as 
shown by the abnormally wide fifth metatarsal, with no phalangeal ossification (Fig. 4B).  
A comparison was made between the limb radiological anomalies noted in patient 2 and 
those found in six unrelated SLOS cases diagnosed at the Department of Pediatrics, Federico II 
University of Naples with available skeletal surveys. These patients showed significant similarities, 
such as toe syndactyly (6/6), and a polydactyly pattern including either post-axial (4/6) or 
interdigital (1/6) extra-digits (Fig.4 C).   
 
Histological features. Skin fibroblasts from patient 2 were propagated in DMEM supplemented 
with 10% fetal bovine serum. Cells were harvested at T0 and after 3 and 7 days of culture in 
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delipidated medium, as previously described [Brunetti-Pierri et al., 2002]. Subsequently, fibroblasts 
were fixed in 2.5% glutaraldehyde in 0.1M cacodylate buffer, postfixed in 1% osmium tetroxide 
and dehydrated through graded alcohols for Epon embedding; sections were stained doubly with 
uranyl acetate and lead citrate and examined by a Zeiss EM-109 electron microscope. 
These cells were compared with skin fibroblasts from two non related SLOS patients diagnosed at 
the Department of Pediatrics Federico II University, and one control, cultured in the same 
conditions. 
The LS cells showed lamellar lysosomal inclusion bodies at T0 (Fig.5A). Fibroblasts from 
two SLOS patients also showed almost indistinguishable lamellar inclusions (Fig.5C). In both cases 
the lamellar vacuoles appeared to be progressively degradated within the lysosomes after three and, 
more extensively, after seven days of culture in delipidated medium (Fig.5B). Control cells did not 
show any sign of storage (Fig.5D).    
 
DISCUSSION 
Cholesterol plays a crucial role in several biological pathways including steroid hormone 
biosynthesis, embryonic development, and the definition of cellular membrane functional 
microdomains interacting with various signaling pathways [Kelley and Herman, 2001; Gondré-
Lewis et al., 2006]. As a consequence of this biological pleiotropy, a disruption in cholesterol 
biosynthesis can lead to a wide range of congenital anomalies with significant clinical variability 
[Kelley and Herman, 2001]. This is well exemplified by the desmosterolosis, a DCB due to the 
deficiency of 3-β-hydroxysterol-∆24-reductase (OMIM: #602398): the two patients described to date 
showed striking differences in their clinical pictures, including micro- and macrocephaly and very 
different patterns of bone mineralization [FitzPatrick et al., 1998; Andersson et al., 2002]. The 
definition of the clinical phenotypes of DCB is crucial to increase the rate of diagnoses and to 
correlate specific patterns of anomalies to the underlying pathogenic mechanisms. LS represents a 
further example of a rare DCB showing significant phenotypic variability even within the same 
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family, as demonstrated by the new case here described. Nevertheless, based on the very few 
patients reported to date, the phenotype of LS appears to be characterized by a recognizable pattern 
of multiple malformations, involving particularly axial and appendicular skeleton, central nervous 
and urogenital systems, partially overlapping with SLOS (Table I).  
 
Facial dysmorphisms 
The neonatal cranio-facial phenotype of our patient 2 is characterized by a marked 
microcephaly (Fig. 2), and shows remarkable similarity to the non related previously described case 
[Parnes et al., 1990]. Figure 2 clearly shows the significant change in her facial appearance occurred 
in the following years, with a gestalt progressively becoming more similar to the SLOS facies.  
 
Axial skeleton 
Patient 1 presented with lumbar meningocele. Neural tube defects (NTD) are a group of 
congenital anomalies ranging from anencephaly, resulting from failure of fusion of the cranial 
neural tube, to spina bifida, resulting from a failure of the vertebral laminae to fuse to complete the 
neural arch, with an overall incidence of approximately 1/1000 [Merbs, 2004; Mitchell, 2005]. 
These malformations have been reported either in MCA/MR syndromes due to chromosomal 
abnormalities (e.g. trisomy 13, 18, and 21), single gene defects (e.g. Meckel-Gruber syndrome, 
OMIM: #249000), and teratogenic exposures (e.g. maternal diabetes), or as isolated defects 
[Mitchell, 2005]. The vast majority of isolated cases are multifactorial and periconceptional folate 
supplementation to the mother has been proved to significantly reduce the incidence of these 
developmental defects [Mitchell, 2005]. Although theoretically there is no definite evidence that the 
occurrence of NTD in the case here described is surely related to the underlying metabolic disease 
and the disruption in cholesterol metabolism, a few clinical and experimental observations might 
support this hypothesis. First, although to the best of our knowledge NTD have never been reported 
to date in biochemically confirmed patients with DCB [Porter, 2003; Kelley and Hennekam, 2000], 
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lumbar meningomyelocele has been described in a case with a clinical diagnosis of CHILD 
syndrome (OMIM: #308050) [Hebert et al., 1987]. Secondly, mice lacking squalene synthase, an 
enzyme involved upstream in cholesterol biosythesis, whose deficiency has not been reported in 
association with human phenotypes until now, do show severe neural tube defects [Tozawa et al., 
1999]. In addition, although studies evaluating apoE and apoB genotypes in patients with NTD 
have failed to find a significant association [Volcik et al., 2002], NTD have been unexpectedly 
described in mice homozygous or heterozygous for mutations of the apoB gene, which plays a key 
role in cholesterol transport [Huang et al., 1995; Homanics et al., 1995].  
Patient 2 presented with an eight thoracic “butterfly” vertebra. Sagittal clefting is a rare 
anatomical defect which has been reported as a part of multiple malformation syndromes, such as 
Alagille syndrome (OMIM: #118450), or as an isolated anomaly [Sonel et al., 2001]. This is the 
result of a developmental error involving the cartilaginous precursor of the vertebral centrum, 
associated with a failure of the notochord to recede [Kjaer et al 1994; Merbs, 2004]. It has been 
demonstrated that DCB are associated with a functional disruption in different steps of the Sonic 
Hedgehog (Shh) pathway, which is essential for embryogenesis and, particularly, for normal 
midline development [Porter, 2003; Hennekam, 2005]. In particular, Shh is expressed in the floor 
plate and the notochord, is required for the specification of the ventral spinal cord [Gofflot et al., 
1999; Lupo et al., 2006], and represents one of the major factors from the notochord and floor plate 
promoting and controlling the formation of the sclerotome, which is the primary origin of the axial 
skeleton [Kornak and Mundlos, 2003]. Therefore, it might be possible to hypothesize that an 
impairment of the Shh pathway, secondary to the defective cholesterol biosynthesis, is responsible 
of the observed vertebral midline defect.  
There is some evidence suggesting that the Shh pathway closely interacts with Zic2 [Brown 
et al., 2003], a zinc-finger transcription factor whose deficiency has been associated in humans with 
either severe midline defects (holoprosencephaly) or NTD [Grinberg and Millen, 2005]. This might 
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suggest a possible pathogenic mechanism explaining the occurrence of either NTD or vertebral 
sagittal defect in LS. 
 
 
Appendicular skeleton 
 The two LS patients here described, presented with postaxial polydactyly associated, in 
patient 2, with toe syndactyly. Both these features were also shown by the non related previously 
reported case, showing hexadactyly with complete metatarsus and phalanges in the left foot, and 
fused fifth and sixth metatarsal bones on the right, associated with bilateral 2-3 toe syndactyly 
[Parnes et al, 1990]. The LS mouse model shows postaxial polydactyly and, in addition, interdigital 
defects with bifurcation of the fourth medial phalanges [Krakowiak et al., 2003]. We compared the 
limb anomalies observed in LS with those found in the SLOS, reviewing the radiological features 
noted in six unrelated SLOS patients, and the findings previously reported in the literature. It is very 
well known that SLOS patients generally present with toe syndactyly, frequently involving the 
second and third toe with a distinctive “Y-shape”, and can have postaxial polydactyly [Ryan et al., 
1998; Kelley and Hennekam, 2000]: in addition, we observed the presence of the less common 
interdigital polydactyly (Fig. 4C). Postaxial polydactyly has been reported also in some of the other 
DCB, such as Greenberg dysplasia (OMIM #215140) and Pelger-Huët homozygosity syndrome 
(OMIM #169400), both of them caused by mutation in the LBR gene  [Oosterwijk et al., 2003], and 
X-linked dominant chondrodysplasia punctata (CDPX2, OMIM #302960), due to the deficiency of 
the enzyme ∆8-∆7-sterol isomerase emopamil-binding protein [Kelley and Herman, 2001]. 
Therefore, the spectrum of limb anomalies, including both postaxial and interdigital polydactyly 
possibly involving the four limbs, and toe syndactyly, appears to be a significant common pattern of 
abnormalities of the appendicular skeleton in DCB.  
Both Sonic and Indian hedgehog are expressed in limbs during embryogenesis, playing a 
central role in regulating the anteroposterior patterning of the limb bud, and the chondrocyte 
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proliferation and hypertrophy, respectively [Kornak and Mundlos, 2003]. Therefore, a functional 
disruption in the hedgehog pathway might well explain the pathogenesis of the DCB common 
pattern of limb anomalies.  
Condrodysplasia punctata was not noted on skeletal surveys performed in infancy in two LS 
patients [patient 2; Parnes et al., 1990]. Although this is a major feature of some of the DCB such as 
CDPX2, Greenberg dysplasia, and CHILD syndrome, to the best of our knowledge it has been 
reported in only one biochemically confirmed SLOS case, who had also a chromosomal 
translocation [Kelley and Hennekam, 2000], and has not been associated to other DCB, such as 
desmosterolosis, and mevalonic aciduria (OMIM: #610377).  
 
Other congenital anomalies 
Both our patient 2 and the non related case previously reported [Parnes et al, 1990; 
Krakowiak et al., 2003] developed bilateral cataracts. Cataract has been reported in some of the 
other DCB such as SLOS, mevalonic aciduria, and CDPX2 and in animal models of DCB such as 
rats treated with the DHCR7 inhibitor AY9944 [Sakuragawa, 1976]. It has been hypothesized that 
the accumulation of abnormal cholesterol precursors might significantly affect lens metabolism and 
that cataract might be considered as a storage disease-like manifestation at least in the SLOS 
[Cenedella, 1996; Elias et al., 1997].  On the other hand, the recent characterization of a rat model 
of hereditary cataract due to the deficiency of another enzyme involved in cholesterol biosynthesis 
named lanosterol synthase, and characterized by reduced cholesterol levels without significant 
precursors accumulations within the lens, has suggested that cholesterol deficiency might itself 
contribute to cataractogenesis too [Mori et al., 2006]. Other ocular findings associated with LS are 
eyelid ptosis, downslanting palpebral fissures, microcorneae and corneal clouding, the latter 
possibly representing another example of storage disease-like manifestations. As in the SLOS, the 
development of male genitalia can be affected in LS [Parnes et al., 1990], while female genitalia 
appeared to be normal in both cases here described. The two patients described post-natally had 
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very severe developmental delay [patient 2; Parnes et al., 1990], in one case associated with 
seizures [Parnes et al., 1990]. The neurological structural abnormalities reported include Type II 
Arnold Chiari malformation, brain atrophy (hydrocephalus “ex vacuo”), demyelination and 
dystrophic calcification: further clinical reports are required to understand whether there is a 
definite pattern of central nervous system malformations in this condition.  
It has been recently reported that LS and SLOS mice models show a marked decrease in the 
number of secretory granules, and an increase of morphologically aberrant granules in exocrine and 
endocrine glands [Gondré-Lewis et al., 2006]. This seems to be the result of the abnormally high 
levels of cholesterol precursors, which significantly affect cell membrane functional microdomains 
playing a key role in granule budding. Further studies are required to clarify whether these 
functional and morphological anomalies are detectable also in LS and SLOS patients, and their 
clinical relevance.  
 
Signs of storage 
An intriguing finding, reported in the non related LS case previously described, was a 
widespread storage of mucopolysaccharides and lipids within histiocytes and the white matter, 
strikingly sparing the neurons, and evident as massive inclusions on optic microscopy; these 
findings were initially misleading, and mucolipidoses were considered in the differential diagnosis 
[Parnes et al., 1990]. No signs of storage were visible on histological examination by optic 
microscopy of either a liver biopsy from patient 2 [Rossi et al., 2005], or various tissues from our 
patient 1, or tissues from LS mouse model [Krakowiak et al., 2003], suggesting that the widespread 
mucolipidosis-like picture previously described does not appear to be a constant feature of LS. 
Since the patient described by Parnes et al. [1990] showed a biochemical defect more severe than 
our patient 2 [Krakowiak et al., 2003], it might be possible to hypothesize that the mucolipidosis-
like picture is associated only with the most severe phenotypes. In this respect, the lack of overt 
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lysosomal storage in both our patient 1 and the LS mouse model might be explained by their pre- or 
peri-natal lethality [Krakowiak et al., 2003].  
On the other hand, vacuolated monocytes were noted on blood film examination of patient 
2, a feature not investigated in the unrelated described patient [Parnes et al., 1990]. Moreover, 
electron microscopy examination of fibroblasts from our patient 2 revealed the presence of 
lysosomal vacuoles with concentric lamellar inclusion, as observed in the non related previously 
reported LS case and in the LS mouse model [Parnes et al., 1990; Krakowiak et al., 2003]. We 
found similar lamellar inclusions also in fibroblasts from SLOS patients (Fig.5C) according to a 
previous observation [Wassif et al., 2002]. These findings share striking morphological similarities 
with the typical lysosomal vacuoles visible in fibroblasts from patients affected by Niemann-Pick 
type C disease (NPC, OMIM: #257220, #607625) [Patterson et al., 2001; Wassif et al., 2002; 
Krakowiak et al., 2003], a lysosomal storage disorder due to mutations of the NPC1 or NPC2 genes, 
and characterized by a defect in cholesterol trafficking. This morphological overlapping has been 
partially explained. In the SLOS, it has been shown that 7-dehydrocholesterol impairs low density 
lipoproteins (LDL) intracellular trafficking and degradation, probably interacting with the NPC1 
protein through its sterol sensitive domain. This results in an accumulation of LDL-derived 
unesterified cholesterol, which can be demonstrated as an increased filipin staining [Wassif et al., 
2002]. A similar effect has been postulated also for lathosterol in LS [Krakowiak et al., 2003]. 
Interestingly the same inclusions can be found also in either a rat model treated with the DHCR7 
inhibitor AY9944 [Sakuragawa, 1976], or in a cell model treated with class 2 amphiphiles, a various 
group of compounds disrupting intracellular lipid trafficking possibly through an inhibition of the 
NPC1 protein function [Lange et al., 2000; Wassif et al., 2002]. In fact, the lamellar bodies might 
be considered the morphological expression of a disruption in intracellular cholesterol trafficking, 
which is the primary defect in NPC, and a secondary defect in LS and SLOS.  
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Similar inclusions have been described also in dermal cells from a case with CHILD 
syndrome [Hashimoto et al., 1998], supporting the hypothesis that disruptions in various steps of 
cholesterol biosynthesis might be associated with an abnormal intracellular lipid trafficking.  
The NPC clinical phenotype shares some similarities with LS, such as developmental delay 
and intrahepatic cholestatic liver disease with high levels of gamma-glutamyl transferase 
[Yerushalmi et al., 2002; Rossi et al., 2005]. Although the presence of lysosomal lamellar 
inclusions on electron microscopy examination and increased filipin staining in skin fibroblasts is 
generally considered pathognomonic of NPC [Patterson et al., 2001], these morphological findings 
can be demonstrated also in LS [Krakowiak et al., 2003]. The lack of multiple malformations, and 
the presence of specific neurological signs such as ataxia or the typical vertical supranuclear 
ophthalmoplegia can clearly differentiate NPC from LS, and in selected cases, tissue sterol profiling 
or molecular analysis of NPC1 and NPC2 genes can be performed for a definite differential 
diagnosis. 
 
Hematology 
Patient 2 showed large platelets, inconstantly low platelet count, and abnormally shaped red 
cells (Fig. 3). Unfortunately no information is available on platelet size and erythrocyte shape for 
the unrelated reported patient [Parnes et al., 1990]. Several factors might contribute to the red cells 
shape abnormalities noted in our patient, such as malabsorption secondary to the severe hepatic 
disease, and abnormal erythrocyte membrane fluidity secondary to the abnormal sterol metabolism 
[Stevenson and Hardie, 2001]. In this respect, it might be interested to notice that achantocytosis is 
also found in disorders of cholesterol transport, such as abetalipoproteinemia (OMIM: #200100) 
and hypobetalipoproteinemia (OMIM: +107730).  
On the other hand, large platelets possibly associated with thrombocytopenia, and 
abnormally shaped red cells (stomatocytes) have been described in Sitosterolemia (OMIM: 
#210250) as part of a complex clinical phenotype including hemolysis, xanthomas, arthritis, 
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accelerated atherosclerosis, and normal psychomotor development. This condition is due to 
mutations in the ABCG5 or ABCG8 genes, which cause an increased intestinal absorption and 
impaired bile excretion of plant sterols and cholesterol, leading to abnormally high plasma levels of 
these compounds. Interestingly our patient 2 repeatedly showed normal to high plasma levels of 
cholesterol in spite of the its biosynthetic defect [Brunetti-Pierri et al., 2002; Rossi et al., 2005], and 
abnormally high levels of plant sterols, even if at lower concentrations comparing with 
Sitosterolemia, this suggesting the presence of a secondary disruption in the metabolism of these 
compounds. The intestinal absorption of cholesterol and plant sterols is regulated by a protein 
named NPC1L1 due to its significant homology to the protein mutated in NPC disease [Davies et 
al., 2000]. Comparing with its homologous, NPC1L1 shows a similar putative sterol sensing 
domain but interacts with different  intracellular targeting signals [Davies et al., 2000; Davis et al., 
2004]; therefore it might be possible to speculate that abnormally high levels of lathosterol could 
interfere also with the NPC1L1 function, determining a secondary disruption in sterols intestinal 
absorption, which could explain the abnormally high plasma levels of plant sterols, the normal to 
high levels of cholesterol, and the platelet abnormalities found in LS patient 2.  
 
Liver involvement 
The liver involvement in patient 2 has been previously extensively described [Rossi et al., 
2005]. Concerning patient 1, some of the hepatic histological abnormalities noted have been 
previously reported among non specific signs of prenatal liver disease in other DBC, such as 
desmosterolosis and Greenberg dysplasia [Clayton, 2003]. Our data suggest that liver involvement 
in LS may range from prenatal hepatopathy to postnatal severe progressive intrahepatic cholestasis.  
A few observations might suggest a possible link between the abnormal plant sterol 
metabolism observed and liver involvement in LS. Mildly high levels of sitosterol have been 
reported in patients with advanced liver diseases such as primary biliary cirrhosis, in association 
with markedly increased levels of cholestanol [Nikkila et al., 2005]; the lack of the latter 
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biochemical abnormality in our patient 2 seems against the possibility that the high levels of plant 
sterols detected are the consequence of her liver disease (Pianese and Corso, personal 
communication). On the other hand, patients affected by Sitosterolemia can present with abnormal 
liver function, cholestatic liver disease and cirrhosis [Miettinen et al., 2006], and it has been 
demonstrated that abnormally high levels of plant sterols can specifically determine cholestasis with 
high levels of GGT in patients on total parenteral nutrition [Clayton et al., 1993; Clayton et al., 
1998]. These observations might suggest that the high levels of plant sterols observed in the LS 
patients, even if at lower concentrations comparing with Sitosterolemia, might contribute to the 
pathogenesis of her liver damage: further studies are necessary to clarify this point and to evaluate 
the possible therapeutic effects of a decreased plant sterol intake on liver function in LS.  
 
 
Conclusion 
In conclusion, we report a further case of LS, contributing to the delineation of the clinical 
phenotype of this condition, which is characterized by the peculiar association of a recognizable 
pattern of multiple malformations and signs of lysosomal storage. Our observation supports a role 
of cholesterol biosynthesis derangement in neural tube closure: patients presenting with a variable 
associations of multiple malformations including NTD, developmental delay, and liver disease 
should undergo plasma or tissue sterol analysis, or molecular analysis of the SC5DL gene. The 
clinical phenotype of LS shows a significant overlapping with other DCB such as the SLOS, and 
shares also similarities with defects of cholesterol trafficking (NPC), and defects of plant sterol 
metabolism (Sitosterolemia), suggesting intriguing pathogenic links among these conditions.  
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TABLE I. Phenotype of lathosterolosis, and comparison with the Smith-Lemli-Opitz syndrome. 
IA. Congenital anomalies. 
CLINICAL FEATURES LS SLOS 
 Patients  
(n. of reports) 
LS mouse 
model 
(frequency %,  
if known) 
Gender 2 female,1 male NA NA 
Growth delay + (2/3) + + 
Intrauterine growth retardation + (1/3) + + (16) 
Postnatal growth retardation + (2/2) NA* + (82-88) 
Facial dysmorphisms + (3/3) + + (100) 
Microcephaly + (3/3) - + (80-84) 
Prominent metopic suture + (1/3) - + 
Eyelid ptosis + (2/3) NA + (59-70) 
Downslanting palpebral fissures + (1/3) NA + 
Cataract  + (2/2) - + (12-22) 
Corneal clouding/Microcorneae + (1/3) - + 
Short nose + (2/3) + + 
Anteverted nares + (1/3) NA + (69-78) 
Micrognathia + (2/3) + + (67) 
Downturned mouth + (2/3) NA + 
High arched palate + (2/3) - + (29) 
Cleft palate -  (0/3) + + (37-47) 
Gingival hypertrophy + (1/3) NA + (37) 
Appendicular skeleton anomalies + (3/3) + + 
Postaxial polydactyly + (3/3) + + (48-49) 
Interdigital defects (complete 
polydactyly, bifurcated phalanges) 
-  (0/3) + + 
Toe syndactyly + (2/3) - + (90-97) 
Clubfeet + (1/3) NA + (27) 
Axial skeleton anomalies + (2/3) - + 
Vertebral clefting + (1/3) - - 
Neural tube defect + (1/3) - - 
Brain structural anomalies + (2/3) - + (21-37) 
Type II Arnold Chiari malformation + (1/3) NA - 
Hydrocephalus “ex vacuo”, 
demyelination, dystrophic 
calcification 
+ (1/3) - + 
Developmental delay + (2/2) NA + (92-95) 
Seizures + (1/2) - + (<5) 
Hearing loss/ abnormal auditory 
evoked potentials 
+ (1/2**) NA + (10) 
Renal malformations + (1/3) - + (29-43) 
Male genital anomalies + (1/1) - + (65-91) 
Liver involvement*** + (3/3) + + (2.5-16) 
Platelet/red cell abnormalities + (1/1) NA - 
References Our patients; [Brunetti-Pierri 
et al, 2002; Krakowiak et al, 
2003; Parnes et al, 1990; 
Rossi et al, 2005] 
[Krakowiak  
et al, 2003] 
Our patients; [Kelley 
and Hennekam 2000; 
Rossi et al, 2005; 
Ryan et al,1998] 
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IB. Signs of storage. 
STORAGE LS SLOS 
 Patients  
(n. of reports) 
LS mouse 
model 
 
Lamellar inclusions (EM) + (2/2) + + 
Mucolipidosis-like inclusions (OM) + (1/3) - - 
Vacuolated monocytes (blood film, OM) + (1/1) NA - 
Fundus oculi cherry red spot -  (0/2) NA - 
Urine mucopolysaccharides and 
oligosaccharides 
-  (0/2) NA - 
References Our patients; [Krakowiak et 
al., 2003; Parnes et al., 1990] 
[Krakowiak 
et al, 2003] 
Our patients; 
[Wassif et al., 
2002] 
 
LS: Lathosterolosis; SLOS: Smith-Lemli-Opitz syndrome; n.: number. 
+: reported; - not reported; OM: Optic microscopy; EM: electron microscopy; NA: not applicable. 
*: early lethality; **: the patient reported by Parnes et al. [1990] had abnormal brainstem auditory evoked 
potentials; our patient 2 had only transient conductive hearing loss; ***ranging from mild prenatal 
involvement to postnatal severe progressive intra-hepatic cholestasis.  
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Figure 1 
Patient 1: liver histology showing normal portal tracts with marked extramedullary hematopoiesis 
leading to atrophy of hepatocytic laminae. Haemosiderinic pigment within periportal hepatocytes 
and Kupffer cells was also noted (detail) (H&E, X200; detail: HepPar, X400). 
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Figure 2 
Patient 2: evolution of facial appearance at different ages. 
2A. Neonatal period: note microcephaly, receding forehead, prominent nose with bulbous nasal tip 
and micrognathia with protruding upper lip. 
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2B. At two years of age; note a significant change in gestalt appearance comparing with the 
neonatal age. 
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2C. At 7 years of age: note microcephaly, epicanthic folds, eyelid ptosis, a small nose with 
anteverted nares, a small chin, and a long philtrum. 
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Figure 3 
Patient 2: hematological features: mp: macroplatelets; aca: acanthocytes; sch: schistocytes; vm: 
vacuolated monocytes (detail) (May-Grunwald Giemsa).  
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Figure 4 
Details from a skeletal survey performed in patient 2 at 11 months of age, and comparison with an 
unrelated patient affected by Smith-Lemli-Opitz syndrome. 
4A. Patient 2: detail of spine radiograph, showing the sagittal clefting of the eight thoracic vertebra, 
“butterfly” shaped (white arrow).  
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4B. Patient 2: detail of feet showing bilateral postaxial polydactyly characterized on the left side by 
an ossified proximal phalanx and abnormal widening of the 5th metatarsal representing an attempt at 
duplication, and, on the right side, abnormally wide fifth metatarsal, with no phalangeal 
ossification. 
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4C. Unrelated SLOS patient: detail of feet. The left foot shows soft tissue syndactyly and 
interdigital polydactyly, with a small extra proximal phalanx in the third and forth web space. In the 
right foot there is postaxial polydactyly with fusion at the base of the fifth and sixth metatarsals. 
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Figure 5 
Electron microscopy examination. 
 5A. Skin fibroblasts from patient 2, at baseline, 16000X. Note the lamellar inclusions (white 
arrows). 
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5B. Skin fibroblasts from patient 2, after 7 days of culture in delipidated medium, 40000X. The 
lamellar vacuoles appear to be progressively degradated within the lysosomes (white arrows).  
 
 68 
5C. Skin fibroblasts from an unrelated Smith-Lemli-Opitz patient at baseline, 13000X, showing 
almost indistinguishable lamellar inclusion bodies (white arrows). 
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5D. Skin fibroblasts from a control, after 7 days of culture in delipidated medium, 12000X, showing 
no sign of storage. 
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CHAPTER 3. 
 
 
 
 
 
 
PROJECT 2: INNOVATIVE THERAPEUTIC 
APPROACHES FOR INHERITED DISORDERS:  
THE MODEL OF POMPE DISEASE 
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3.1 Background 
3.1.1 Pompe disease (Glycogenosis type II). 
Pompe disease, also known as glycogenosis type II, is an autosomal recessive progressive metabolic 
myopathy with an estimated incidence of 1:40,000 live births (Hirschhorn and Reuser, 2001; 
Kishnani and Howell, 2004). This condition is due to mutations of the acid α-glucosidase gene, 
(GAA)  encoding the lysosomal hydrolase α-glucosidase (acid maltase, GAA), which is synthesized 
as a 110 kDa precursor and is processed into the active polypeptides of 76 and 70 kDa, through an 
intermediate molecular form of 95 kDa (Hirschhorn and Reuser, 2001; Kishnani and Howell, 2004).  
The biochemical defect determines tissue glycogen accumulation and secondary muscle destruction. 
Different mutations of the GAA gene result in a wide phenotypic variability, spanning a continuum 
range. The severe classic infantile form is characterized by early onset, severe hypertrophic 
cardiomyopathy, marked hypotonia, macroglossia, hepatomegaly, and invariably fatal outcome by 
one year of age. The late onset (childhood, juvenile or adult) form is characterized by skeletal 
myopathy, possible respiratory failure and absence of significant cardiac disease. Current 
classifications identify intermediate phenotypes, such as the non-classic infantile form, presenting 
within the first two years of life, with less severe heart involvement and absence of left ventricular 
outflow obstruction (Hirschhorn and Reuser, Kishnani and Howell, 2004; 2001; Slonim et al., 
2000). It has been shown that an inverse correlation generally exists between degrees of clinical 
severity and different ranges of residual enzymatic activity (Hirschhorn and Reuser, 2001; Kishnani 
and Howell, 2004). 
Enzyme replacement therapy (ERT) with recombinant human alpha-glucosidase derived from either 
rabbit milk or Chinese Hamster Ovary cells, has been recently introduced and is currently under 
evaluation (Amalfitano et al., 2001; Van den Hout et al., 2000; Winkel et al., 2004). Although some 
promising experimental data on gene therapy have been reported in animal models (Sun et al., 
2005), to date no therapeutic approaches are available for Pompe patients, other than ERT. 
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3.2 Experimental work 
3.2.1 Outline of the project 
The overall aim of this project was to develop innovative therapeutic approaches for Pompe disease. 
The different steps of the project specific aims are summarized hereafter, and the clinical, 
biochemical and molecular results of this studies are reported “in extenso” in the appendices 3.5.1, 
3.5.2, and 3.5.3 of this chapter.  
 
3.2.2 Patients 
We collected eight Pompe patients followed up by our Department or other local hospitals: their 
clinical features are summarized in Table 1 (section 3.2.3). In all cases the diagnosis was confirmed 
by GAA enzymatic assay in cultured skin fibroblasts or muscle biopsy, carried out as previously 
described (Hirschhorn and Reuser, 2001). The patients were characterized also by molecular 
analysis of the GAA gene performed in collaboration with Dr. Pittis and Dr. Bembi, Unità di 
Malattie Metaboliche, I.R.C.C.S. Burlo Garofolo, Trieste, Italy, and Dr. Filocamo, Laboratorio di 
Diagnosi Pre e Postnatale Malattie Metaboliche, I.R.C.C.S. G. Gaslini, Genoa, Italy: some of the 
molecular results were included in an Italian multicenter collaborative study, enclosed in appendix 
3.5.3 (patients BAP, VPO, DPF are respectively patients 6, 40 and 1 in the paper by Montalvo et al., 
2006).  
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3.2.3. Table 1. 
Pompe patients recruited for our research project 2.  
Patients 
  Age at 
diagnosis 
Main clinical features at diagnosis 
DCME Classic infantile 5m Muscle hypotonia, severe cardiomyopathy, 
pneumonias, raised serum muscle enzymes 
RGG  Classic infantile 6y Muscle hypotonia, severe cardiomyopathy, 
pneumonias, raised serum muscle enzymes 
 
RP  Infantile onset 
non-classic 
1y Hypotonia, motor delay, pneumonias, raised serum 
muscle enzymes 
GM Infantile onset 
non-classic 
11m Motor delay, frequent vomiting and failure to thrive, 
raised serum muscle enzymes 
BAP Childhood-
onset 
4y Muscle weakness, raised serum muscle enzymes 
PP Juvenile 11y Muscle weakness, scoliosis, low respiratory tract 
infections, raised serum muscle enzymes 
VPO Juvenile 2y2m Motor delay, hepatomegaly, raised serum muscle 
enzymes 
DPF Juvenile 3y Hypotonia, raised serum muscle enzymes 
 
Note: m: months; y: years. 
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3.2.4 Specific aim 1.  
EVALUATION OF THE LONG TERM EFFECTS OF ENZYME REPLACEMENT 
THERAPY OF POMPE DISEASE WITH RECOMBINANT HUMAN ΑLPHA-
GLUCOSIDASE (DERIVED FROM CHINESE HAMSTER OVARY CELLS). 
We studied the long term safety and efficacy of ERT with recombinant human alpha-glucosidase 
derived from Chinese Hamster Ovary cells on three of the Pompe cases recruited (GM, RP and 
VPO), all of whom presenting without cardiomyopathy. The patients were treated at dose regimens 
of 20-40mg/Kg/every other week. Follow-up length ranged from 20 weeks to 140 weeks of therapy. 
The first patient (GM), who underwent enzyme replacement therapy earlier and in better baseline 
conditions, showed motor improvement and no respiratory failure. The second case (RP) who 
started the therapy early, in severe general conditions, showed improvement in motor function and 
degree of disability, but not in muscle strength. Significant respiratory improvement was also noted: 
following enzyme replacement therapy, the frequency of low airway infections markedly decreased 
and the patient, who was ventilator-dependent at baseline, became steadily ventilator-free for short 
periods. The third case (VPO), who started the therapy at a terminal stage of a long lasting disease, 
died shortly after. Our study suggests that enzyme replacement therapy can lead to significant motor 
and respiratory improvement in the subgroup of patients who start the therapy before extensive 
muscle damage has occurred. The recombinant enzyme derived from Chinese Hamster Ovary cells, 
administered at doses significantly higher than previously reported, appears to have the same safety 
as the rabbit milk derived drug. This study is fully reported in appendix 3.5.1.  
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3.2.5 Specific aim 2.  
EVALUATION OF THE EFFECTS OF IMINO SUGARS ON MUTATED ALPHA-
GLUCOSIDASE ACTIVITY IN FIBROBLASTS FROM PATIENTS WITH POMPE 
DISEASE 
In this study, we tried to evaluate the feasibility of an alternative therapeutic approach in an “in 
vitro” model of Pompe disease. Our aim was to provide the proof of principle for developing an 
enzyme enhancement therapy using pharmacological chaperones. We studied the effects of two 
imino sugars, deoxinojirimycin (DNJ) and N-butyldeoxynojirimycin (NB-DNJ), on residual GAA 
activity in fibroblasts from the 8 patients recruited, presenting with different forms of Pompe 
disease  (2 classic infantile, 2 non-classic infantile onset, 4 late onset forms), and with different 
mutations of the GAA gene. We demonstrated a significant increase of GAA activity (1.3 to 7.5-
fold) after imino sugar treatment in fibroblasts from patients carrying the mutations L552P (3 
patients) and G549R (1 patient). GAA enhancement was confirmed in HEK293T cells where the 
same mutations were overexpressed. No increase of GAA activity was observed for the other 
mutations. Western blot analysis showed that imino sugars increase the amount of mature GAA 
molecular forms. Immunofluorescence studies in HEK293T cells overexpressing the L552P 
mutation showed an improved trafficking of the mutatnt enzyme to lysosomes after imino sugar 
treatment. These results provide a rationale for an alternative treatment, other than enzyme 
replacement, to Pompe disease. This study is fully reported in appendix 3.5.2.  
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3.3 Conclusions 
In this study we evaluated the effects of two experimental innovative therapeutic strategies for 
Pompe disease. Our data suggested that ERT has controversial results on Pompe patients: in fact 
this treatment appears to prevent motor regression and lead to motor and respiratory improvement 
in Pompe patients who start the therapy before a significant muscle damage has occurred. 
Nevertheless, the lack of significant effects of the treatment on severely compromised skeletal 
muscle, supports the need of alternative therapeutic approaches. The results of the “in vitro” study 
evaluating the use of small molecules with “chaperone” effect on Pompe cells can provide the 
rationale for an alternative therapy.  Future studies might be focused on evaluating the “in vitro” 
effects of the combination of enzyme enhancement therapy and ERT and, ultimately, on the 
feasibility of clinical trials based on this innovative therapeutic approach.  
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ABSTRACT 
Pompe disease is a rare autosomal recessive myopathy due to the deficiency of lysosomal acid 
alpha-glucosidase. Clinical phenotypes range from the severe classic infantile form, characterized 
by hypotonia and hypertrophic cardiomyopathy, to the childhood, juvenile and adult forms 
characterized by skeletal myopathy and absence of significant heart involvement. Enzyme 
replacement therapy with recombinant human alpha-glucosidase derived from either rabbit milk or 
Chinese Hamster Ovary cells, has been recently introduced and employed in still ongoing clinical 
trials. We report on a long term follow-up of three Pompe cases presenting without 
cardiomyopathy, treated with recombinant human alpha-glucosidase derived from Chinese Hamster 
Ovary cells at dose regimens of 20-40mg/Kg/every other week. The first patient, who underwent 
enzyme replacement therapy earlier and in better baseline conditions, showed motor improvement 
and no respiratory failure. The second case who started the therapy early, in severe general 
conditions, showed improvement in motor function and degree of disability, but not in muscle 
strength. Significant respiratory improvement was also noted: following enzyme replacement 
therapy, the frequency of low airway infections markedly decreased and the patient, who was 
ventilator-dependent at baseline, became steadily ventilator-free for short periods. The third case, 
who started the therapy at a terminal stage of a long lasting disease, died shortly after. Our study 
suggests that enzyme replacement therapy can lead to significant motor and respiratory 
improvement in the subgroup of patients who start the therapy before extensive muscle damage has 
occurred. The recombinant enzyme derived from Chinese Hamster Ovary cells, administered at 
doses significantly higher than previously reported, appears to have the same safety as the rabbit 
milk derived drug.  
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INTRODUCTION 
Pompe disease, also known as glycogenosis type II, is an autosomal recessive progressive metabolic 
myopathy with an overall incidence of 1:40000 live births. 1,2 This condition is due to the deficiency 
of the lysosomal enzyme alpha-glucosidase, leading to tissue glycogen accumulation and secondary 
muscle destruction. 2 The phenotype of the disease is characterized by clinical variability, spanning 
a continuum range. The severe classic infantile form is characterized by early onset, severe 
hypertrophic cardiomyopathy, marked hypotonia, macroglossia, hepatomegaly, and invariably fatal 
outcome by one year of age. 3 The late onset (childhood, juvenile or adult) form is characterized by 
skeletal myopathy, possible respiratory failure and absence of cardiac disease. 4,5 Current 
classifications identify intermediate phenotypes, such as the non-classic infantile form, presenting 
within the first two years of life, with less severe heart involvement and absence of left ventricular 
outflow obstruction. 1,2,4,6 It has been shown that an inverse correlation generally exists between 
degrees of clinical severity and different ranges of residual enzymatic activity. 2 
Enzyme replacement therapy with recombinant human alpha-glucosidase derived from either rabbit 
milk or Chinese Hamster Ovary cells, has been recently introduced and is currently under 
evaluation. To date the results of only four trials have been published, enrolling a total of nine cases 
with classic infantile form and three cases with late onset Pompe disease; 7,8,9,10,11,12,13 in particular, 
information about treatment with the recombinant alpha-glucosidase derived from Chinese Hamster 
Ovary cells is to date available only for three patients presenting with significant cardiomyopathy 
(classic infantile Pompe disease), and followed up for one year. 9  
Given the phenotypic variability of this condition, the limited number of patients on treatment, the 
different sources of recombinant human alpha-glucosidase and the various dosages used for enzyme 
replacement therapy in the few published studies, even single observations may provide useful 
information on either the clinical course or the therapeutic outcome. We report on three Pompe 
patients presenting without significant cardiac involvement, treated with recombinant human alpha-
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glucosidase derived from Chinese Hamster Ovary cells, who provide additional information on the 
effects of this experimental therapeutic approach. 
 
PATIENTS AND METHODS 
Three patients with Pompe disease were recruited in an observational study; their clinical and 
biochemical features are summarized in Table 1. Written informed consent was obtained from 
either patients and/or parents, and the therapy was approved by the local ethical committee. The 
drug was provided by Genzyme Corporation (Myozyme ®). Case 1 was enrolled in the expanded 
access protocol for infantile onset Pompe disease (AGLU 02203); case 2 received the drug for 
compassionate use; case 3 was enrolled in the protocol for severely affected cases with late onset 
Pompe disease (AGLU 02503). 
Cases 1, 2 and 3 started the enzyme replacement therapy at 3 years and 8 months, 2 years and 8 
months, and 19 years and 9 months of age respectively. Case 1 and 3  were on 20mg/Kg/every other 
week (qow); case 2 started the therapy at the dosage of 10mg/Kg/week, which was gradually 
increased to 40mg/Kg/qow (Table 1). Periodic clinical assessments included physical examinations, 
and neuro-developmental assessments performed by a pediatric neurologist and psychologist. 
Muscle function was evaluated with the Gross Motor Function Measure. This scoring system 
evaluates the patients’ skills on the bases of the following five different dimensions: “lying and 
rolling”; “sitting”; “crawling and kneeling”; “standing”; “walking, running and jumping”. The 
calculated scores for each dimension are the result of the percentage of performance items reached 
by the patient. After the age of 4 years, muscle functional impairment was also measured according 
to the Walton and Gardner-Medwin scale, an 11-points ordinal scale ranging from grade 0 (patient 
performing all activities) to grade 10 (patient confined to bed and requiring help for all activities). 
Manual Muscle Testing according to the Medical Research Council score 14 was used to assess 
specifically muscle strength after the age of 4 years. The following muscles were evaluated, 
separately for each side of the body when appropriate: neck flexors and extensors, deltoids, biceps, 
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triceps, wrists flexors and extensors, hip flexors and abductors, knee flexors and extensors, foot 
dorsal and plantar flexors. Scores were given to each muscle (scores ranging from 0: no movement, 
to 5: normal strength) and were added to obtain a total muscle score for upper body (maximum 
score: 50), lower body (maximum: 60) and total body (maximum: 110). Mental and cognitive status 
was evaluated by Bayley Scales of Infant Development II and WPPSI tests, according to the age 
and general conditions of the patients. In all cases, the degree of disability was evaluated using the 
Pediatric Evaluation of Disability Inventory: 15 the Normative Standard Score, expressed as a 
percentile (mean + 2 standard deviations corresponding to a score of 50 + 20), was evaluated to 
measure the child overall functional performance relative to peers; the Scaled Score provided an 
estimate, regardless of age, of the child’s functional performance along a continuum of items scored 
from 0 to 100. 
Audiometry was performed every 6 months. Biochemical analyses included full blood count, serum 
levels of alanine transaminase, aspartate transaminase, lactate dehydrogenase, creatine kinase, 
bilirubin, alkaline phosphatase, electrolytes, glucose, creatinine, urea, uric acid, bicarbonate, 
protein, albumin, and urine analysis. Anti-recombinant human alpha-glucosidase antibodies were 
analyzed by enzyme-linked immunosorbent and radioimmunoprecipitation assays by Genzyme 
Corporation. Muscle biopsy was repeated during enzyme replacement therapy at week 12 and week 
77 only in case 2. 
 
RESULTS 
Growth parameters and general conditions 
A total of 153 infusions were performed during the observational period. Our three cases underwent 
enzyme replacement therapy with variable degrees of muscular damage and general conditions 
severity (Table 1).  
Case 1, who started the therapy before a significant muscular damage occurred, remained in good 
conditions during the whole observational period. Comparing baseline with week 70, weight 
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improved from the 5th to the 10-25th centile, while stature and head circumference remained 
between the 10th and the 25th centile, and between mean and -2 standard deviations, respectively. 
In case 2 baseline weight, length and head circumference were all below the 5th centile (Kg 10.220, 
cm 85 and cm 47 respectively, at 32 months of age). During enzyme replacement therapy, a gradual 
improvement in growth parameters was noted and, at week 135, her weight was Kg 20 (75th), length 
cm 108 (25th) and head circumference cm 51 (between mean and +2 standard deviations). Her 
general conditions, which were critical at baseline due to significant motor impairment and 
respiratory failure, slowly improved. After a 57 weeks admission in a Pediatric Intensive Care Unit 
(37 weeks of enzyme replacement therapy) she was allowed to go home for a few hours-days/week 
and, at week 124, she eventually became an outpatient.  
At baseline, case 3 was already at a terminal stage of the disease and had a very wasted build 
(weight: Kg 26). It was not possible to measure stature, because of the severe kypho-scoliosis and 
multiple joint contractures. 
Motor assessment 
Case 1, who had only a mild motor impairment at baseline, showed a significant improvement of 
muscular function during follow-up, and no regression. The “walking, running and jumping” 
dimension of the Gross Motor Function Measure score was 86% at baseline, 93% at week 12, and 
steadily 100% since week 26; the other dimensions were steadily 100% (Figure 1A). Walton and 
Gardner-Medwin scale grade and Manual Muscle Testing scores were always normal. 
Case 2, who had been able to stand at 2 years of age, at baseline could not hold her head, but was 
only able to lift her arms for a short time, with her lower limbs laying down in a frog-like position. 
After enzyme replacement therapy was started, she stopped losing motor skills, and re-achieved 
some major motor milestones: at week 70, the patient was able again to sit unsupported and to 
manipulate objects, but she could stand only with multiple orthopedic devices. Although this girl 
was not able to speak properly, partly due to the prolonged use of invasive respiratory support, she 
could efficiently communicate with gestures. The dose of the recombinant enzyme was gradually 
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increased up to a maximum of two times the initial dosage, and motor function evaluated by Gross 
Motor Function Measure showed a significant improvement. In the first year of therapy, the scores 
for the “lying and rolling” and “sitting” dimensions gradually improved from 9.8% to 37.3%, and 
from 0% to 43.3% respectively (Figure 1B); nevertheless, after two years of therapy, the girl 
reached a plateau score (52.9% and 55% respectively) and subsequently did not further improve, 
despite continuous physiotherapy (Figure 1B). The other Gross Motor Function Measure 
dimensions were steadily 0% during follow-up. The Walton and Gardner-Medwin scale grade, 
evaluated from week 70, confirmed the impression of a steady state, being constantly 8. Muscle 
strength, evaluated from week 70 with Manual Muscle Testing, initially improved but subsequently 
declined in spite of the drug dose increase (Figure 2).  
Case 3 underwent enzyme replacement therapy with a baseline skeletal muscle function very 
severely compromised by the long lasting disease (Table 1) (Manual Muscle Testing total scores for 
upper body: 23, lower body 11, total body: 34).  
In all three cases cognitive and intellectual skills were not impaired (data not shown). 
Orthopedic complications 
Case 1, who underwent enzyme replacement therapy with a very mild impairment of muscle 
function, never experienced orthopedic complications.  
Case 2, who underwent enzyme replacement therapy with a significant degree of muscular damage, 
experienced a few orthopedic complications. Despite continuous physiotherapy, she developed joint 
contractures at lower limbs from week 27: at week 77 she underwent surgical operation for clubfeet. 
At week 84, a pathologic fracture of the left femoral neck occurred, requiring surgical reduction, 
immobilization for 19 weeks and vitamin D supplementation for a complete recovery. Total body 
DEXA scan performed at week 124 did not show generalized osteoporosis (Z score: -0.1, normal 
values for age >-2.5), although it was not possible to rule out the presence of localized areas of 
osteopenia secondary to immobility. Bilateral hip dislocation and scoliosis of the thoracic and 
lumbar tract were noted at week 88 and 130 respectively.  
 126 
Case 3 had severe contractures of knees and ankles and a very marked kypho-scoliosis from 
baseline. 
Disability evaluation 
Case 1 had a Pediatric Evaluation of Disability Inventory score within normal range through the 
whole follow-up period, without any significant decrease. Case 2 showed a significant increase 
particularly in the social function and self care domains (Figure 3), although the mobility domain 
scores remained steadily below the 10th centile, as compared with peers. Case 3 showed a 
significant degree of disability (baseline Functional Skills Scaled Score: Self care: 30.7; Mobility: 
11.4; Social function: 52).   
Respiratory function 
During the follow-up period, case 1 had recurrent upper airway infections and otitis, but he neither 
experienced pneumonia nor developed respiratory failure. 
At baseline case 2 was on intermittent mandatory ventilation with 20-25 breaths/min, and oxygen 
supplementation (FiO2: 0.6-0.7) (Figure 4). In the following weeks, she had several lung infections 
(Figure 4) causing left lung atelectasia. A tracheostomy was performed at week 12. During 
treatment, the frequency of respiratory infections progressively decreased and a gradual 
improvement in respiratory function was observed. She was gradually weaned from intermittent 
mandatory ventilation and, since week 25, she was on continuous positive airway pressure only 
(Figure 4). From week 37, the patient could stay without any respiratory support, initially for a few 
hours during the day and then, gradually, for a few days (up to 8 days between weeks 56 and 57). 
At week 58, continuous permanent continuous positive airway pressure was required after another 
episode of low respiratory tract infection and, since week 61, she was on a pressure support 
ventilation, with no need of active ventilation (positive end-expiratory pressure: 0-4 cmH2O; 
pressure support: 10 cmH2O); since week 68, she was again steadily able to stay without respiratory 
support for 1-2 hours/day (Figure 4) 
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During the whole follow-up period, case 3 was on continuous intermittent mandatory ventilation 
through tracheostomy, with oxygen supplementation during most of the nights for about 8 
hours/night, and daytime only during upper respiratory tract infections.  
Cardiac status 
Electrocardiogram and echocardiography, scheduled every 3 months for infantile Pompe patients 
and every 6 months for the late onset case, did not show signs of hypertrophic cardiomyopathy. 
Hearing assessment 
Case 1 had recurrent otitis but no significant hearing problems. Conductive hearing loss due to 
recurrent otitis was demonstrated in case 2 since week 36, and at week 134 grommets were inserted. 
Mild mixed hearing loss was detected in case 3 by audiometry at week 9. 
Global outcome 
While a significant improvement was noted in case 1 and 2, case 3 unfortunately suddenly died 
after only 20 weeks of enzyme replacement therapy; it was not possible to perform autopsy, and the 
death was considered to be likely related to the severe pre-therapy general conditions.  
Laboratory tests 
In all cases, creatine kinase serum levels tended to increase, transaminases levels tended to decrease 
and lactate dehydrogenase levels were variable over time with no definite trend: these variations 
were statistically significant for alanine transaminase serum levels in case 1 (R2: 0,7802) and 
creatine kinase serum levels in case 2 (R2: 0.3054) (Figure 5).  
For case 3, creatine kinase and aspartate transaminase levels were respectively 302 and 92 IU/L at 
baseline and 395 and 89 IU/L at week 20.  
Repeated muscle biopsies, performed only in case 2 at weeks 12 and 77 during surgical procedures, 
did not show major histological changes as compared to the sample obtained at diagnosis.  
Safety evaluation 
In all cases, blood pressure and heart rate showed only minor changes during the infusions.  
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Case 2 experienced a few adverse events from week 2, consisting of transient abdominal pain, 
accumulation of secretions in the upper airways, irritability, fatigue, transient hypoxia and moderate 
fever (up to 38.5°C), easily managed with administration of paracetamol, reduction of the infusion 
rate and occasional pre-medication with prometazine and paracetamol. Anti-recombinant human 
alpha-glucosidase IgG were positive since week 6 with increasing titers (at week 6: 6400; at week 
7: 3200; at weeks 10 and 13: 25600; at weeks 17, 70, 76, 114, 124 and 140: steadily 12800). 
Case 1 and 3 never experienced infusion related adverse events. In case 1, the anti-drug IgG were 
negative until week 20, and then became positive at variable titers (at weeks 20, 26, 38, 52, and 64: 
200, 400, 800, 800, 400 respectively). Concerning case 3, anti-drug IgG were negative until week 
12 and then became positive at increasing titers (at weeks 12, 16 and 20: 400, 400, 800 
respectively). 
Repeated urine analyses were normal and, in particular, did not show proteinuria.  
 
DISCUSSION 
This observational study reports on the use of recombinant human alpha-glucosidase derived from 
Chinese Hamster Ovary cells in Pompe patients presenting with no cardiac involvement, focusing 
particularly on long term safety and efficacy. Little information about the effects of this drug is 
currently available in the literature: the only published study described the drug effects observed in 
classic infantile Pompe patients during a yearly follow-up at a dose regimen of 5mg/Kg/twice 
weekly. 9 Subsequently it has been suggested that the administration of a higher quantity of 
recombinant enzyme, less frequently might be more effective. 11 In the present study, the drug was 
administered at a dose of 20mg/Kg/qow in 2 cases. Moreover, case 2 was treated with increasing 
doses of recombinant enzyme, up to a maximum of 40mg/Kg/qow, and was followed for up to three 
years. Our data confirm that enzyme replacement therapy with recombinant human alpha-
glucosidase derived from Chinese Hamster Ovary cells, performed at doses significantly higher 
(two times) than previously reported, has the same safety as the rabbit milk derived drug. 
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Only a single trial has been reported to date, enrolling Pompe patients presenting with no heart 
involvement: 11 in this study, three juvenile Pompe cases were treated with the rabbit milk derived 
recombinant enzyme and showed motor improvement and stabilization of pulmonary function. 11 
Our observation suggests that the recombinant enzyme derived from Chinese Hamster Ovary cells 
has a similar efficacy in childhood Pompe disease. In particular, concerning respiratory status, our 
case 2 showed a remarkable decrease of the frequency of lung infections and a significant reduction 
in the need of respiratory support after the therapy was started (Figure 4). Ventilator dependency 
has been considered an exclusion criterion in studies on classic infantile Pompe patients. 7,10 Two 
previously described late onset patients, who were ventilated and showed severe scoliosis at the 
start of therapy, did not show significant improvement in pulmonary function. 11 This is the first 
description of a Pompe patient who was ventilator-dependent at baseline and, following enzyme 
replacement therapy, eventually became steadily ventilator-free for short periods. Our observation 
suggests that improvement in respiratory function is possible in baseline ventilated patients, if the 
therapy is started before the occurrence of significant muscle destruction and/or significant 
scoliosis.  
Concerning motor status, case 1 showed no regression and a complete normalization of his motor 
skills. On increasing drug doses, case 2 showed controversial results. She had a gradual 
improvement in muscle function, stopping losing motor skills and progressing significantly in 
motor development. Nevertheless, she reached a plateau at around week 114 and neither major 
improvement nor decline was subsequently noted (Figure 1). The degree of motor disability 
improved significantly (Figure 3). On the other hand, after week 70, muscle strength initially 
slightly improved and subsequently showed a mild decline (Figure 2). 
A few different factors might explain the different outcome of the observed cases. The phenotypic 
clinical variability of the disease is likely to affect the global outcome of the patients. Before 
starting enzyme replacement therapy, case 2 had a significantly worse clinical course than case 1, in 
spite of an early presentation in both cases; this might fit with the previous observation that, among 
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patients presenting before the age of 15 years, there is a subgroup with a more severe and rapid 
course of the disease. 16 It has been suggested that glycogen clearance by enzyme replacement 
therapy is likely to lead to a more significant clinical improvement, the earlier the therapy is started, 
and the less skeletal muscle fibers have been damaged to an irreversible degree. 13 It is possible to 
hypothesize that the lack of significant effects of enzyme replacement therapy on muscle strength 
and the occurrence of orthopedic complications in case 2, might be due to the severe muscle 
destruction already established at baseline, and not further amenable to treatment. In this respect, 
the higher baseline degree of clinical severity associated with the longer disease duration 16 may 
well explain the very poor global outcome of case 3.  
Although to the best of our knowledge pathological fractures and hip dislocations have not been 
reported in the previously published trials, we believe that Pompe patients should be strictly 
monitored for these events, which are very likely to be secondary to reduced mobility. 
We did not observe significant changes in muscular histology after one year and a half of therapy in 
case 2; this is in agreement with previous observations suggesting a possible little of even absent 
histological change in Pompe patients on enzyme replacement therapy, 7,10 and emphasizing that 
muscle pathology can vary significantly between different muscle bundles examined. 11  
During enzyme replacement therapy, we observed an increasing trend for creatine kinase levels and 
a decreasing trend for transaminases. While muscle enzymes have been reported to be useful 
biochemical diagnostic tools for Pompe disease, 5 their significance in the follow-up of Pompe 
patients is currently a matter of debate. Lactate dehydrogenase and transaminases have been 
proposed to be better markers of disease progression in the natural history of classic infantile 
Pompe disease, as compared with creatine kinase; 3 on the other hand creatine kinase levels have 
been considered to be the best serologic marker of enzyme replacement therapy efficacy in late 
onset Pompe disease. 11 It might be reasonable to hypothesize that both muscle and liver contribute 
to the abnormally high levels of transaminases found in Pompe patients. The discrepancy between 
decreasing transaminases serum levels and increasing values of creatine kinase might suggest that 
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enzyme replacement therapy is more effective on liver than muscle, probably because the drug is 
up-taken more efficiently by the hepatocytes compared with skeletal muscle fibers. 17 Comparing 
the increasing creatine kinase levels found in our patients treated with the Chinese Hamster Ovary 
cells derived drug, with the decreasing creatine kinase levels previously reported in three cases 
treated with the rabbit-milk derived recombinant drug, 11 one might hypothesize a more significant 
effect on skeletal muscle of the latter drug. No studies have been reported to date systematically 
comparing the effects of the two drugs available. Nevertheless, in the very few observational studies 
published to date, the efficacy of both alternative drugs on motor status seems to be variable and 
overall comparable. 18   
The presence of anti-drug antibodies in our cases was difficult to interpret. Case 2 developed anti-
drug antibodies at increasing titers in the first months of treatment, when she showed significant 
clinical improvement. On the other hand, when she subsequently stopped improving in muscular 
function and showed a slight decline in muscular strength, she had stable anti-drug serum levels. 
Case 1 and 3, who developed anti-drug antibodies at lower and comparable levels, had a very 
different outcome. On the basis of our findings and the previously reported observations, the 
clinical relevance of the anti-drug antibodies appears unclear and requires further investigation. 11  
Our case 3 started enzyme replacement therapy in very poor general conditions and died after only 
20 weeks of treatment. We think that positive results are more likely to be submitted for publication 
than the negative ones. This might explain the fact that, among a total of twelve Pompe patients 
reported in the literature on enzyme replacement therapy, there is only one death report. 10 Further 
descriptions of cases with poor outcome might contribute to the identification of the subgroup of 
patients who might be more likely to improve on enzyme replacement therapy.  
The lack of significant effects of the treatment on severely compromised skeletal muscle, suggests 
the need of alternative therapeutic approaches: experimental data about gene therapy in animal 
models, 19 and preliminary data on the effects of small molecules with chaperone effect in “in-vitro” 
models of Pompe disease, 20 seem to be promising. 
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In conclusion, our observations provide additional information on the efficacy and safety of enzyme 
replacement therapy with recombinant human alpha-glucosidase derived from Chinese Hamster 
Ovary cells, suggesting that this experimental therapeutic approach can prevent motor regression 
and lead to motor and respiratory improvement in Pompe patients who start the therapy before 
significant muscle damage has occurred. 
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FIGURE LEGENDS 
 
Figure 1 
Cases 1 and 2: effects of the enzyme replacement therapy on muscle function measured by the 
Gross Motor Function Measure. For details of the scoring system: see text.  
 
1A: Case 1. The scores for the “lying and rolling”, “sitting”, “crawling and kneeling” and 
“standing” dimensions were steadily 100% (not shown). 
 
1B: Case 2. The scores for the “standing” and “walking, running and jumping” dimensions were 
steadily 0 (not shown). 
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Figure 2 
Case 2: Manual Muscle Test total scores, evaluated during treatment from week 70 according to the 
Medical Research Council, for upper body (circles), lower body (squares), and total body 
(triangles). 
For details about the test: see the text.  
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Figure 3 
Case 2: degree of disability assessed during enzyme replacement therapy using the Pediatric 
Evaluation of Disability Inventory. For details about the test: see text.  
3A: Normative Standard Scores. Normal range: 30-70. Mobility domain (both functional skills and 
caregiver assistance): always <10th centile (data not shown). 
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3B: Scaled Score. 
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Figure 4 
Case 2: infectious episodes and respiratory support. After enzyme replacement therapy was started, 
the frequency of lung infections (black arrows) decreased over time and respiratory function 
gradually improved. 
Note: white arrows: start of enzyme replacement therapy, and subsequent changes in the drug dose; 
qow: every other week.  
Respiratory support:  
A: Continuous intermittent mandatory ventilation (at baseline: 20-25 breaths/min; in the following 
weeks: 5-25 breath/min depending on patient’s conditions) and continuous oxygen supplementation 
(FiO2 0.5-0.7).  
B: Intermittent mandatory ventilation during nighttime or infectious episodes (5-15 breaths/min 
depending on patient’s conditions); continuous positive airway pressure during daytime in 
infection-free periods. Intermittent oxygen supplementation (FiO2 0.21-0.7).  
C: Continuous positive airway pressure; no oxygen.  
D: Continuous positive airway pressure/no oxygen/no respiratory support for short periods (few 
hours/few days)   
E: Continuous pressure support ventilation; no oxygen. F: Pressure support ventilation/no 
oxygen/no respiratory support for short periods (few hours).  
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Figure 5 
Cases 1 and 2: effects of the enzyme replacement therapy on serum levels of creatine kinase 
(circles), aspartate transaminase (triangles), and alanine transaminase (squares).  
Note: IU: International Units; L: Liter 
5A: Case 1. 
5B: Case 2. 
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Table 1. 
Features of the three Pompe patients. m: months; y: years; qow: every other week. 
Patients (Gender, patient’s initials) 1 (Male, GM) 2 (Female, RP) 3 (Male, VPO) 
Onset 4m 6m 2y 
Age of diagnosis 11m 1y 2y2m 
Presenting symptoms/signs    
Hypotonia - + - 
Motor delay + + + 
Frequent vomiting, failure to thrive + - - 
Hepatomegaly - - + 
Hypertrophic cardiomyopathy - - - 
Raised serum muscle enzymes + + + 
Enzymatic activity at diagnosis (% of lower limit of normal range) 
Muscle  0.46 3 - 
Fibroblasts  1.8 4 2.4 
Lymphocytes  - 8 3.3 
Baseline conditions    
Skeletal muscle involvement + + + 
Motor regression - + + 
Severe hypotonia - + + 
Wheelchair bound - + + 
Severe scoliosis - - + 
Joint contractures - - + 
Pathologic fractures - - + 
History of pneumonias - + + 
Respiratory failure - +  + 
Invasive ventilation - + + 
ERT    
Age at the start  3y8m 2y8m 19y9m 
Follow-up duration (weeks) 70 140 20 
Dose (weeks) 20mg/Kg/qow (0-70) 10mg/Kg/week (0-69); 
20mg/Kg/qow (70-85); 
30mg/Kg/qow (86-95); 
40mg/Kg/qow (96-140) 
20mg/Kg/qow 
(0-20) 
Global outcome Improvement Improvement Death 
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ABSTRACT 
We investigated the use of pharmacological chaperones for the therapy of Pompe disease, a 
metabolic myopathy due to mutations of the gene encoding the lysosomal hydrolase α-glucosidase 
(GAA) and characterized by generalized glycogen storage in cardiac and skeletal muscle. We 
studied the effects of two imino sugars, deoxinojirimycin (DNJ) and N-butyldeoxynojirimycin (NB-
DNJ), on residual GAA activity in fibroblasts from 8 patients with different forms of Pompe disease  
(2 classic infantile, 2 non-classic infantile onset, 4 late onset forms), and with different mutations of 
the GAA gene. We demonstrated a significant increase of GAA activity (1.3 to 7.5-fold) after imino 
sugar treatment in fibroblasts from patients carrying the mutations L552P (3 patients) and G549R (1 
patient). GAA enhancement was confirmed in HEK293T cells where the same mutations were 
overexpressed. No increase of GAA activity was observed for the other mutations. Western blot 
analysis showed that imino sugars increase the amount of mature GAA molecular forms. 
Immunofluorescence studies in HEK293T cells overexpressing the L552P mutation showed an 
improved trafficking of the mutatnt enzyme to lysosomes after imino sugar treatment. These results 
provide a rationale for an alternative treatment, other than enzyme replacement, to Pompe disease. 
 
Key words  
Pompe disease, glycogen storage disease, α-glucosidase, imino sugar, deoxynojirimycin, N-
butyldeoxynojirimycin, enzyme enhancement, pharmacological chaperone  
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INTRODUCTION 
Pompe disease (PD, glycogenosis type II, OMIM 232300) is an autosomal recessive disease with an 
estimated incidence of 1:40,000 live births [1]. PD is due to mutations of the acid α-glucosidase 
(GAA) gene, encoding the lysosomal hydrolase α-glucosidase (acid maltase, GAA, E.C.3.2.1.20), 
which is synthesized as a 110 kDa precursor and is processed into the active polypeptides of 76 and 
70 kDa, through an intermediate molecular form of 95 kDa  [1, 2].  
α-Glucosidase deficiency results in generalized tissue glycogen accumulation and secondary 
cardiac and skeletal muscle destruction [3]. Different mutations of the GAA gene result in a wide 
phenotypic variability, ranging from the devastating classic infantile form, characterized by early 
onset, severe hypertrophic cardiomyopathy, marked hypotonia, hepatomegaly, and invariably fatal 
outcome by one year of age, to the late onset childhood, juvenile or adult forms, characterized by 
skeletal myopathy, in the absence of cardiac disease [3]. Infantile onset non-classic phenotypes 
have been described, presenting within the first two years of life, with milder or absent heart 
involvement [3, 4]. 
Enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA) derived from either 
rabbit milk or Chinese Hamster Ovary (CHO) cells has been recently introduced in the treatment of 
PD patients [5,6]. The results of the published trials, enrolling more than thirty cases with variable 
phenotypes, support the effectiveness of ERT on cardiomyopathy and motor function in the classic 
infantile PD patients, whereas the effects of ERT on skeletal myopathy in the late-onset patients 
were variable [7]. Concern about the efficacy of ERT on skeletal muscle manifestations also derives 
from a number of studies performed in animal models, showing preferential targeting of rhGAA to 
liver, rather than to muscle [8], little or no clearing of glycogen stores from muscle cells in 
advanced stage skeletal muscle involvement [8, 9], selective resistance of type II muscle fibers to 
ERT with rhGAA [10]. These observations suggest that a search for alternative therapeutic 
approaches to PD, other than ERT, is warranted, particularly for patients with late-onset forms and 
prominent skeletal muscle disease. 
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Recently, the use of pharmacological chaperones to enhance the activity of mutated lysosomal 
enzymes has attracted considerable interest. It has been shown that specific drugs, mostly imino 
sugars and their alkylated derivatives, are able to rescue the deleterious effects of missense 
mutations on the folding and activity of several lysosomal hydrolases, including β-
glucocerebrosidase [11], α-galactosidase [12,13], β-galactosidase [14] and β-hexosaminidase [15]. 
It has been proposed that the enhancing effect of these compounds may have applications in the 
treatment of lysosomal storage disorders due to the deficiency of these enzymes. 
In this study we have explored the possibility of using this approach in PD. We have investigated 
the effects of two imino sugars, deoxynojirimycin (DNJ) and N-butyldeoxynojirimycin (NB-DNJ), 
on GAA activity in fibroblasts from PD patients carrying different mutations of the GAA gene.  
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RESULTS 
Molecular characterization of patients 
Seven out of 8 patients included in the study were characterized on the molecular ground. The 
results of the molecular analysis of patients are reported in Table 1. The mutation L552P was found 
in three unrelated patients (28% of the alleles studied) coming from different Regions of Italy. 
Patients 1 was homozygous for this mutation, whereas patients 2 and 3 were heterozygotes, both 
carrying the L552P mutation together with a splicing mutation c.-35C>A and the A445P mutation, 
respectively. Patient 4 was a compound for the mutation G549R and a splicing mutation. Patients 5 
and 7 were homozygous for two missense mutations (L355P and R375L, respectively). In patient 6 
only a single allele, carrying a c.-45T>G mutation, commonly associated with juvenile phenotypes, 
was identified. Patient 8 died before the molecular analysis was performed and her parents could 
not be traced back to provide a parental consent to mutational analysis. 
 
Effects of imino sugars on GAA activity in PD fibroblasts 
We studied the effects on GAA activity of the imino sugar DNJ and its alkylated derivative NB-
DNJ in fibroblasts from the PD patients included in the study. Treatment for 9 days with both 
compounds was effective in enhancing GAA activity in fibroblasts from patients 1-4 (Fig. 1). A 1.8 
to 5.6-fold increase of residual GAA activity after treatment with NB-DNJ was observed in 
fibroblasts from patients 1, 2 and 3, carrying at least one allele with the L552P mutation and from 
patient 4, carrying the missense mutation G549R and a splicing mutation on the second allele.  
Similar results (1.3 to 7.5-fold increase in GAA residual activity) were obtained after culturing the 
same fibroblast cell lines in the presence of DNJ. In all cases GAA increases from baseline were 
statistically significant with values of p ranging from <0.001 to 0.019.  
 150 
The maximum increase of GAA activity reached approximately 10% of the low normal range in 
control fibroblasts. No increase was found in cells from patients 5-8. No effect on GAA activity was 
observed in control fibroblasts after imino sugar treatment.  
NB-DNJ concentrations as low as 10 µM were sufficient to enhance GAA activity, reaching a 
plateau between 10 and 80 µM (Fig. 2A). The enhancing effect was already observed after 3 days of 
incubation and continued up to15 days (Fig. 2B). 
No increase of GAA activity was observed when PD fibroblasts were cultured in the presence of 20 
µM concentrations of different imino sugars (deoxygalactonojirimycin and mannojirimycin) 
suggesting a specific effect of DNJ and NB-DNJ on GAA (not shown). 
 
Effects of imino sugar treatment on single mutations expressed in HEK293T cells 
To study the effects of imino sugar treatment on single alleles, each of the missense mutations 
found in responsive patients was transiently expressed in HEK293T cells. According to the studies 
on the time course of imino sugar enhancement in fibroblasts a treatment period of 3 days is 
sufficient to obtain a detectable effect on GAA catalytic activity. 
GAA activity was measured in homogenates from NB-DNJ treated and untreated transfected cells 
and the results were compared (Fig. 3). Imino sugar treatment of HEK293T cells transfected with 
constructs carrying the mutations L552P and G549R, resulted in an increased GAA activity. These 
results are consistent with those obtained in fibroblasts. No increase was found when the mutation 
A445P was expressed. This suggests that in patient 3, who is a compound for the mutation L552P 
and the A445P, the contribution of the latter mutation to GAA enhancement is negligible. In the 
HEK293T cells expressing the mutation R375L no enhancement by imino sugar treatment was 
observed, confirming the results obtained in fibroblasts from patient 7 (homozygous for this 
mutation).  
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Expression of GAA mRNA and protein  
To investigate the mechanism involved in the enhancement of GAA activity, mRNA transcription 
and protein expression were studied in PD fibroblasts and in transfected HEK293T cells.  
Real time PCR was performed on the cDNA prepared from imino sugar-treated and untreated 
fibroblasts from patient 1 (homozygous for the responsive mutation, L552P), patient 7 
(homozygous for the unresponsive mutation R375L) and a normal control. Imino sugar treatment 
did not influence the expression of GAA mRNA in all cell lines studied (not shown).  
Western blot analysis of GAA peptides was performed in imino sugars responsive and in non 
responsive fibroblasts. In the fibroblasts showing enhancement of GAA activity, imino sugar 
treatment resulted in an appreciable increase of mature GAA polypeptides. Figure 4 shows the 
results obtained in fibroblasts from patient 1, homozygous for the L552P mutation, and showing the 
highest GAA increase, and from patient 4, carrying the other imino sugar responsive mutation 
G549R on one allele.  
The 110 kDa precursor is detectable in all untreated cells. In fibroblasts from patient 1 after NB-
DNJ treatment the amount of precursor is unchanged and the 70-76 kDa peptides are faint but 
clearly appreciable. In fibroblasts from patient 4, a compound for the responsive G549R mutation 
and a splicing mutation, a reduced amount of the mature 70-76 kDa peptides is already detectable 
under basal conditions and remains unchanged after imino sugar treatment. In both cases the 
amount of mature GAA polypeptide is low, as compared to that observed in controls, consistent 
with increases of enzyme activity of no more than 10% of normal values. Imino sugar treatment 
resulted in an increased amount of mature GAA peptides also in fibroblasts from patient 7, in which 
no enzyme activity enhancement had been observed. It is likely that the R375L mutation, detected 
in the unresponsive patient, has a severe impact on GAA catalytic activity, thus explaining the lack 
of enzyme enhancement by imino sugars.  
Western blot analysis was also performed in NB-DNJ treated and untreated transfected HEK293T 
cells (Fig. 5). In all cells, expressing each of the missense mutations studied, imino sugar treatment 
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resulted in increased amounts of both the 95 kDa intermediate and the mature GAA 70-76 kDa 
polypeptides, confirming the results obtained in fibroblasts. The observation of an increased amount 
of mature GAA in cells expressing the non-responsive mutations A445P and R375L, further 
supports the idea that specific mutations impact severely on the functional domains of the enzyme 
and that in these mutants GAA activity cannot be rescued by pharmacological chaperones, even if 
the maturation of the protein is improved. 
 
Immunolocalization of mutant GAA in HEK293T cells 
To investigate whether imino sugar improve the trafficking of GAA to the lysosomal compartment 
immunofluorescence studies were performed in HEK293T cells overexpressing the mutation 
L552P. In the cells expressing mutated GAA imino sugar treatment resulted in a punctate staining 
typical of lysosomal localization and comparable to that obtained in the same cells expressing the 
wild type enzyme (Fig. 6). The GAA fluorescence partly co-localized with a lysosomal protein 
(LAMP2), thus confirming an improved delivery of GAA to lysosomes. 
 
 
DISCUSSION 
We have shown that treatment with the imino sugars DNJ and NB-DNJ enhances the activity of 
GAA in fibroblasts from patients with specific mutations of the GAA gene.  
DNJ and NB-DNJ are known inhibitors of glycosidases, including GAA, and ceramide-specific 
glucosyltransferases [16]  and were initially proposed for clinical use as anti-HIV drugs [17]. NB-
DNJ is presently approved for the treatment of Gaucher disease in humans, as a substrate-reducing 
agent, and is commercially available. In principle, the same inhibitory effect on the synthesis of 
glucosphingolipids may be useful for the treatment of other disorders, including GM1 and GM2 
gangliosidoses and Niemann-Pick disease type C.   
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It has recently been shown that, in addition to the effect on substrate synthesis, NB-DNJ is able to 
perform as a pharmacological chaperone on β-glucocerebrosidase, and that it can rescue the effects 
of specific mutations of this enzyme (including the common N370S associated with Gaucher 
disease type 1) [11]. The concept of pharmacological chaperones that can rescue misfolded, 
unstable and non-functional proteins is a growing field of investigation and the possible 
applications in human therapy are currently under investigation [18-20]. The use of specific 
chemical chaperones has been proposed also in other lysosomal storage diseases, such as Fabry 
disease [12, 13], GM1 [14] and GM2 gangliosidoses [15]. In Fabry disease this approach had a 
clinical application [21] and proved to be effective in reducing cardiac hypertrophy in a patient with 
the cardiac variant of the disease.  
We demonstrated a similar effect of imino sugars DNJ and NB-DNJ on residual GAA activity in 
fibroblasts from PD patients with different genetic backgrounds and different phenotypic 
presentations.  
Since some patients were genetic compounds for different GAA gene mutations, the enhancing 
effects of imino sugars were studied in human kidney cells expressing single mutant alleles. This 
allowed to clarify that two of the mutations studied were responsive to imino sugar treatment. The 
L552P mutation results in the change of a lysine into a proline residue, which may induce a turn in 
the protein tertiary structure and can be implicated in protein misfolding. Although most missense 
mutations of the GAA gene are rare or private mutations, the L552P mutation appeared to be 
relatively frequent in our series of patients (28% of the alleles). The other responsive mutation 
changes a glycine into an arginine (G549R). Both the L552P and the G549R mutations are localized 
close to the GAA catalytic domain, where it is likely that interactions with DNJ and NB-DNJ occur, 
while the unresponsive mutations (A445P, L355P and R375L) are localized in different domains of 
the protein. Studies on the tertiary structure of GAA will probably provide an important tool to 
better understand the mechanisms leading to GAA enzyme enhancement by pharmacological 
chaperones and to identify other responsive mutations.  
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To study the mechanisms implicated in enzyme enhancement the effects of imino sugars on GAA 
mRNA transcription and protein maturation were analyzed in cultured fibroblasts from responsive 
patients, and compared to the results obtained in a non-responsive cell line and in controls.  
Imino sugars had no significant effect on mRNA levels, that remained unchanged in all cell lines 
studied. Western blot analysis of fibroblasts and HEK293T cells expressing single GAA gene 
mutations showed the presence of substantial amounts of the mature and active 76-70 kDa GAA 
molecular forms after treatment with imino sugars. This indicates that enzyme enhancement is 
mediated through an improved maturation and/or stability of the enzyme. Increased amounts of 
GAA polypeptides was observed in all cell lines studied, also in the absence of enzyme activity 
enhancement. This indicates that, although imino sugars are generally effective in increasing the 
amount of mature GAA, in the presence of specific GAA gene mutations GAA catalytic activity 
cannot be rescued.  
Immunofluorescence studies in cells overexpressing the L552P mutation showed that imino sugars 
enhance the trafficking and delivery of mutated GAA to lysosomes. 
An important issue to be addressed is whether the enhancing effect of DNJ and NB-DNJ in vitro 
has potential relevance for therapeutic applications. In this respect, although it appears paradoxical 
that the same molecule that inhibits a lysosomal enzyme is able to enhance its activity by improving 
protein folding and stability, a number of observations suggest that the use of pharmacological 
chaperones may not affect the enzyme catalytic activity within the lysosomal compartment, and 
therefore might be beneficial for patients.  
First, it has been shown that NB-DNJ does not increase muscle glycogen content in mice at plasma 
concentrations comparable to those reached in human therapy (between 2 and 30 µM), and that 
glycogen storage in muscle is observed only when high doses of drug (2400 mg/kg/day) are 
administered to the animals [22]. In our study we found that an enhancing effect of imino sugars on 
GAA is already detectable at concentrations of 10-20 µM, therefore lower than those potentially 
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causing glycogen accumulation. 
Second, it has been suggested that imino sugars concentrations attained in lysosomes are lower that 
those in the endoplasmic reticulum [22] and that the interactions between imino sugars and the 
catalytic site of the enzymes are pH dependent and do not occur at acidic pH [12]. 
Also, it can be speculated that imino sugars are displaced from the catalytic site of the enzyme by 
the excess of natural substrate, such as glycogen, accumulated in the lysosomes. 
During the preparation of our manuscript, an in vitro study was published showing a stabilizing 
effect on GAA of high concentrations of glucose in the culture medium of CHO-K1 cells 
expressing wild-type GAA [23]. In the same study an enhancing effect on GAA activity by glucose 
was described in adult onset PD fibroblasts, although no information on the molecular background 
of the patients was provided. Although these data are consistent with our findings on GAA enzyme 
enhancement in PD, high levels of glucose would not be appropriate for human therapy, due to 
possible deleterious metabolic effects. 
Our results appear promising in terms of possible clinical applications of imino sugars for the 
treatment of PD. One of the drugs tested in our study, NB-DNJ, has been used for treatment of 
Gaucher disease for more than 5 years [16] and wide clinical experience on the use of this drug is 
already available. In our study we obtained a significant increase of GAA activity in fibroblasts 
from patients with responsive mutations, up to approximately 10% of the low normal GAA activity 
in fibroblasts. The GAA specific activity obtained in fibroblasts treated with imino sugars is 
comparable to the activity detected in muscle from GAA knock-out mice treated with high doses 
(100 mg/kg/week) enzyme replacement therapy [8].  Such an increase may impact on patients’ 
phenotypes and clinical course. For several lysosomal diseases a threshold effect has been 
demonstrated, and it has been shown that even low residual enzyme activities are sufficient to 
prevent substrate accumulation. In PD a clear correlation between enzyme activity and the severity 
of the phenotype has been observed, with undetectable GAA in the severe forms of the disease and 
substantial residual activity in milder and late onset forms [1]. 
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In conclusion, our results indicate an alternative therapeutic strategy based on the stimulation of 
endogenous residual GAA, at least in some patients with PD.  An in vitro evaluation of imino 
sugars effect may be a preliminary step in recognizing individual patients in whom an enzyme 
enhancement-based approach could be beneficial. 
 
PATIENTS AND METHODS 
Patients 
Patients 1 and 2 (Table 1) with the non-classic infantile onset form of the disease presented with 
generalized hypotonia and myopathy within the first year of life. They did not show cardiac 
involvement and are presently alive at ages of 6 and 5 years, respectively. Patient 1 is presently 
wheel chair-bound and needs respiratory support. Patients 3 presented at 3 years of age with 
respiratory infections, hypertransaminasemia and progressive motor regression. She is presently 
wheel chair-bound at the age of 20 years. Mild cardiac involvement is also present. Patient 4 
presented at the age of 4 years with mild generalized weakness and hypertransaminasemia, without 
signs of cardiac disease, and is presently alive at the age of 11 years. Patient 5 presented in the third 
year of life with hepatomegaly and muscular weakness, progressively leading to respiratory 
insufficiency and death at the age of 20 years. Patient 6 presented in the third year of age with lower 
limb hypotonia and hypertransaminasemia. He is presently 13 years old and shows generalized 
weakness, without cardiac involvement. Patients 7 and 8 presented with severe cardiomyopathy and 
generalized hypotonia. In both cases their phenotype was typical of the classic infantile PD. They 
died at ages of 13 and 14 months, respectively. Patients 1-6 were on enzyme replacement therapy 
for variable periods. 
 
Reagents and chemicals 
Unless otherwise stated all reagents were purchased from Sigma-Aldrich (St Louis, MO, USA).  A 
polyclonal antiserum against human GAA developed in rabbit was available in our laboratory. DNJ 
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and NB-DNJ were dissolved in DMSO at a concentration of 4.5 mM; appropriate amounts of this 
stock solution were added to cell culture media to obtain the required final concentrations in the 
different experiments. Glucose concentration in the medium was 4500 mg/L. 
 
Cell cultures 
Fibroblasts cell lines were cultured from skin biopsies, after obtaining an informed consent by the 
patients’ parents. Both fibroblasts and human kidney embryonic cells HEK293T were grown in 
DMEM, supplemented with antibiotics and glutamine. Glucose concentration in the medium was 
4500 mg/L.  
 
Molecular characterization of patients 
The mutational analysis of the GAA gene was performed according to reference [24] after obtaining 
an informed consent from the patients’ parents. Genomic DNA from the patients was obtained from 
peripheral blood, using commercial kits, according to standard procedures. Oligonucleotides 
corresponding to intronic sequences flanking all GAA exons were used as primers to amplify single 
exons by PCR. Cycle sequencing was performed in the forward and reverse directions with the ABI 
Prism Big Dye Terminator Cycle Sequencing kit (Applied Biosystem, Warrington, UK). Sequence 
analysis was performed on an automated ABI Prism 3700 sequencing apparatus. 
 
Treatment of fibroblasts with imino sugars  
Fibroblasts from each patient were incubated for 9 days with 20 µM DNJ and 20 µM NB-DNJ, 
respectively. The same cell lines were cultured in parallel in the absence of imino sugars for 
comparison. The optimal concentrations of imino sugars to be used and the time course of GAA 
enzyme enhancement were determined in fibroblasts from patient 1 that were cultured for variable 
times (0, 3, 6, 9, 15 days) in the presence of different concentrations (0, 10, 20, 50, 80 µM) of NB-
DNJ. After each experiment the cells were harvested and cell extracts were used for the assay of 
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GAA activity and for Western blot analysis. To test the specificity of different imino sugars, 
fibroblasts were also cultured for 9 days in the presence of 20 µM concentrations of deoxy-
galactonojirimycin and mannojirimycin. 
 
Expression of GAA mRNA in PD fibroblasts 
Total RNA was extracted from treated and untreated cell cultures using RNeasy mini kit protocols 
(Qiagen). RNA concentrations were determined using Cary 50 Bio Spectrophotometer (Varian). 
The SuperScript First Strand Synthesis System for RT-PCR (Invitrogen) was used to generate 
cDNA for PCR from 1 µg of total RNA. Real time RT-PCR was performed using I cycler IQ 
Detector System (BioRad). GAA cDNA was amplified using a forward primer in GAA exon 1 (5’ 
TCTGAAATGGGCTACACGGC 3’) and a reverse primer in GAA exon 2 (5’ 
CGCTGTTAGCTGGATTG 3’). The relative amount of transcripts was calculated by using the 
threshold cycle (Ct) methods, according to the manufacturer’s instructions, comparing GAA versus 
Beta-Actin transcripts. Real time PCR reactions of each sample were performed in triplicate and 
experiments were repeated at least three times. 
 
Site directed mutagenesis and expression of mutated GAA in mammalian cells 
GAA cDNA was obtained as described [24]. The mutations identified in patients were introduced in 
the wild type GAA gene by site-directed mutagenesis, using commercially available kits (Quick-
Change, Stratagene), according to the manufacturer’s instructions and using primers carrying the 
mutations identified in patients. The cDNAs were subcloned in pCDNA3 and human embryonic 
kidney cells HEK293T were transiently transfected with 2 µg wild type and mutant cDNAs by 
commercially available kits (PolyFect, Quiagen), according to the manufacturer’s instructions. 
Immediately after transfection the cells were incubated in the presence of 20 µM NB-DNJ. Seventy-
two hours after transfection the cells were harvested and cell homogenates were used for the assay 
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of GAA activity and for Western blot analysis.  
 
GAA enzyme assay 
Fibroblasts and HEK293T cells were harvested by trypsinization and disrupted by freezing and 
thawing (3x). Cell homogenates (30-40 µg of protein) were incubated at 37° for 60 minutes with 2 
mM 4-methylumbelliferyl α-D-glucopyranoside as substrate in a 0.2 acetate buffer buffer pH 4.0 in 
an incubation mixture of 100 µl. Reactions were stopped with 1.9 ml glycine carbonate buffer pH 
10.7 and fluorescence was read on a Turner biosystems fluorometer Modulus 9200 (360 nm  
excitation, 450 nm  emission). Protein concentration in cell homogenates was measured according 
to reference [25]. 
 
Western blot analysis  
Equal amounts (20 µg protein) of fibroblast or HEK293T cell homogenates were subjected to SDS-
PAGE electrophoresis and Western blotting. To detect the GAA polypeptides a polyclonal anti-
GAA antiserum raised in rabbit was used as primary antiserum. The different GAA polypeptides 
were visualized using an alkaline phosphatase-conjugated goat anti-rabbit secondary antiserum. To 
detect β-actin polypeptides a monoclonal anti β-actin antibody developed in mouse was used as 
primary antibody and the filters were developed by ECL, according to standard procedures. Extracts 
from untreated cells and control fibroblasts were run in parallel for comparison. 
 
Immunolocalization of mutant GAA in HEK293T cells 
Immunofluorescence studies were performed according to ref  [24], using a rabbit polyclonal anti-
GAA antiserum as a primary antibody and a FITC-conjugated anti-rabbit IgG (DAKO, Glostrup, 
Denmark). For co-localization studies a monoclonal anti-LAMP2 antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was used as a primary antibody and a TRITC-conjugated 
anti-mouse antiserum as a secondary antibody (DAKO, Glostrup, Denmark). 
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Statistical analysis 
The statistical significance of the effects of imino sugar on GAA activity in  fibroblasts was 
evaluated by Mann-Whitney test. The variation of RNA expression in treated and untreated 
fibroblasts levels was analyzed statistically by a T-test. 
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Figure 1 
Effects of imino sugars treatment in Pompe fibroblasts. 
Treatment with NB-DNJ and DNJ resulted in increased GAA activity in patients 1-4. Mean, 
standard deviations and statistical significance, derived from 4-10 independent experiments for each 
patient are indicated.  
No increase was found in fibroblasts from patients 5-8. 
NCI = non classic infantile. J = juvenile. CI = classic infantile. 
GAA activity in control fibroblasts was 58.5 +/- 28.1 nmoles 4-methylumbelliferone liberated/mg 
protein/hour. 
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Figure 2 
Effects of different imino sugar concentrations (A) and time course of GAA enhancement (B) 
in fibroblasts from patient 1.  
Enhancement of GAA activity was observed at NB-DNJ concentrations between 10 and 80 µM. 
The enhancing effect of 20 µM NB-DNJ was already observed after 3 days of incubation and 
continued up to15 days. 
Each point is mean of 2 different experiments. 
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Figure 3 
Effects of NB-DNJ in HEK293T cells expressing wild-type and mutated GAA.  
Increase of GAA activity after NB-DNJ treatment was observed in HEK293T cells expressing the 
mutations L552P and G549R. No increase was observed in the cells expressing the mutations 
A445P and R375L. The specific activities indicated at the top of each bar are the mean of three 
independent experiments. The activities are expressed as nmoles 4-MU liberated/mg protein/hour.  
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Figure 4 
Western blot analysis of fibroblast. 
The figure shows the results obtained in fibroblasts from patients 1, 4 (imino sugar responsive), 7 
(non responsive) and from an untreated control cell line.  The cells were cultured for 9 days with (+) 
and without (-) 20 µM NB-DNJ. The arrows indicate the bands corresponding to a precursor 
peptide of approximately 110 kDa and the mature active molecular forms (76-70 kDa).  
In all cell lines an increase of the mature 70-76 kDa GAA molecular forms was observed.  The 
results of Western blot analysis were consistent and reproducible in four independent experiments.  
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Figure 5 
Western blot analysis of HEK293T cell extracts expressing single mutations of the GAA gene.   
After transfection the cells were cultured for 72 hours with (+) and without (-) 20 µM NB-DNJ. The 
arrows indicate the bands corresponding to a precursor peptide of approximately 110 kDa, the 
intermediate 95 kDa and the mature active molecular forms (76-70 kDa). In treated cells an increase 
of the mature 70-76 kDa GAA molecular forms was observed. 
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Figure 6 
Confocal analysis of immunolocalization of GAA in HEK293T expressing L552P mutated 
GAA in the absence and in the presence of NB-DNJ and in cells expressing wild type GAA.  
In the cells expressing the L552P mutation in the absence of imino sugar treatment negligible 
immunofluorescent labelling for GAA was observed (a). NB-DNJ treatment of the cells resulted in 
an enhancement of immunofluorescent labelling for GAA with a punctate staining typical of 
lysosomal localization (b). This pattern is comparable to that observed in the same cells expressing 
the wild type enzyme (c).  
The same cells were stained for an endogenous lysosomal marker (LAMP2) (d, e, f). In cells 
overexpressing the L552P mutated GAA in the presence of NB-DNJ, and in cells overexpressing 
the wild type enzyme, the fluorescent labelling for GAA partly co-localized (h, i), thus confirming 
an improved delivery of GAA to lysosomes. 
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Table 1. 
Phenotype and genotype of PD patients  
 
Genotype Patient 
(initials) 
 
cDNA  mutation Protein mutation 
1655T>C L552P 1 (RP) Infantile onset 
non-classic 1655T>C L552P 
1655T>C L552P  2 (GM) Infantile onset 
non-classic 
c.-35C>A abnormal splicing 
1655T>C L552P 3 (PP) Juvenile 
1333G>C A445P 
1645G>C  G549R  4 (BAP) Childhood-onset 
c.692+1G>C abnormal splicing 
1064T>C L355P 5 (VPO) Juvenile  
1064T>C L355P 
c.-45T>G abnormal 
splicing 
6 (DPF) Juvenile  
unknown  
1124G>T 
 
R375L  7 (DCME) Classic infantile 
1124G>T R375L 
8 (RGG) Classic infantile n.a. n.a. 
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